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Although the incidence of breast cancer in women under 40 years of age is somewhat 
rare, young women tend to present with cancer that is more advanced and with poorer 
prognostic characteristics. This research will be important to providers, women and their 
families and those seeking to clarify screening guidelines. The purpose of this 
quantitative, retrospective, cohort study was to evaluate differences in prognostic 
characteristics by socioeconomic position (SIP). The cohort was comprised of females 
aged 18 to 39 with a primary diagnosis of breast cancer. Data were obtained from the 
Surveillance, Epidemiology and End Results registry for all primary breast cancers 
reported between 2001 and 2006 (n = 14,696). Hierarchical regression analysis was 
performed to assess to what extent SEP had an independent effect on tumor size and 
cancer summary stage upon diagnosis, and overall survival. SEP was found to be a 
significant predictor of tumor size and summary stage at the time of diagnosis. As cancer 
summary stage increases by 1 unit, women were .14 times as likely to have a tumor size 
of less than 2 cm versus a tumor size of greater than 5 cm. As SEP increases by 1 unit, 
the likelihood of having a tumor size of less than 2 cm versus greater than 5 cm increases 
by a factor of 1.14. SEP was not a significant predictor of survival time. The results of 
this study have the potential to promote positive social change by advancing the 
understanding of breast cancer in young women, as well as raise awareness of 
socioeconomic, racial and clinical inequalities. In addition, it may assist researchers and 
policy makers clearly defined formal screening guidelines for young women in higher-
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Chapter 1: Introduction to the Study 
Background of the Study 
Breast cancer is the second leading cause of cancer death among women in the 
United States and the first cause of cancer related deaths globally (Kohler et al., 2011; 
World Health Organization [WHO], 2010). Although the incidence of breast cancer in 
women under 40 years of age is somewhat rare, young women tend to present with 
cancer that is more advanced, and with poorer prognostic characteristics—such as tumor 
size and how far the cancer has spread within the body (Fisher et al., 2001; Rapiti et al., 
2005; Rosenberg, Chia, & Plevritis, 2005). On national and global scales, there are 
apparent socioeconomic, racial and ethnic health disparities in breast cancer incidence, 
and survival (Baquet, Mishra, Commiskey, Ellison, & DeShields, 2008; Harper et al., 
2009). Between 2001 and 2005, African-American women with breast cancer had a 37% 
higher mortality rate than European-American women (Ries et al., 2008). 
Additionally, barriers to care have been identified as factors that impede early 
detection of breast cancer in minorities, thus contributing to this disparity. Researchers of 
a study performed in 2006 (Lantz et al., 2006) noted that approximately 66.6% of 
European-American women had detected their breast cancer through screening 
mammography, in comparison to 54.6% of African-American women, and 48.5% of 
Hispanic women (p <.001). In 1996, Weiss et al. found that in women under the age of 
35, 30% had detected their breast cancer through mammography, 6% through a physical 
exam, and 5% due to clinical symptoms such as breast pain, swelling, dimpling, mastitis, 





In a study performed in 2003, found that patients who resided in low income 
neighborhoods were significantly more likely to present with Stage IIIB breast cancer or 
higher in comparison to patients who lived in neighborhoods of a higher income (33% vs. 
24%; O'Malley, Le, Glaser, Shema, & West, 2003). Additionally, O’Malley et al. (2003) 
found that the women presenting with late-stage disease were more likely to live in the 
low education (30%) and blue-collar neighborhoods (29%). 
Table 1  
Frequencies for Newly Diagnosed Breast Cancer Cases Taken from the SEER 17 
Registry Matching the Criteria for This Proposed Study 
 
Age 18-39 
(n = 14,936)  
Age 40-80 
(n = 217,653) 
  n (%)   n (%) 
Caucasian  8,524 (57.07%)   161,036 (73.99%) 
African-American  2,037 (13.64%)   19,453 (8.94%) 
American Indian/Alaska Native  101 (0.68%)   951 (0.44%) 
Asian or Pacific Islander  1,517 (10.16%)   15,110 (6.94%) 
Spanish-Hispanic-Latino  2,622 (17.55%)   19,624 (9.02%) 
Other / Unspecified  24 (0.16%)   236 (0.11%) 
Other / Unspecified-with Hispanic 
Surname  9 (0.06%)   77 (0.04%) 
Unknown  90 (0.60%)   1,089 (0.50%) 







It is projected that approximately 1 out of 8 American women will develop 
invasive breast cancer during their lifetime (Altekruse et al., 2010). It was estimated that 
in the year 2010, there were 207,090 new cases of invasive breast cancer and 54,010 
cases of in situ breast cancer diagnosed among women (ACS, 2010a). Breast cancer is the 
second leading cause of cancer death among women in the United States, with an 
estimated 39,840 deaths in the year 2010 (ACS, 2010a).  
There are approximately 250,000 or more women living in the United States who 
were diagnosed with breast cancer under the age of 40, and an expected 10,000 more 
young women will be diagnosed over the next year (Young Survival Coalition [YSC], 
2010). Although the incidence of breast cancer in young women (under the age of 40) is 
somewhat rare, young women (under the age of 45) tend to present with cancer that is 
more aggressive and with poorer prognostic characteristics (Anders et al., 2008; Brinton, 
Sherman, Carreon, & Anderson, 2008; Hartley et al., 2006; Yankaskas, 2006). Breast 
cancer is the leading cause of cancer related deaths among women ages 15 to 54 
(National Cancer Institute [NCI], 2006a).  
Between the years 2003-2006 the median age of all adult women newly diagnosed 
with breast cancer was 61; women under 40 accounted for approximately 6% of new 
cases (Horner et al., 2009). During that same time period, the overall age-adjusted 
incidence rate was 122.9 per 100,000 women per year (Altekruse et al., 2010). 
Subsequent age-specific incidence rates were 0.0% for girls and women under age 20, 





54; 24.1% between 55 and 64; 19.5% between 65 and 74; 15.8% between 75 and 84; and 
5.6% for women aged 85 or above (Altekruse et al., 2010). 
Until recently, women were encouraged to begin breast self-exams (BSEs) at age 
20 and yearly mammograms at age 40 (ACS, 2009b; NCI, 2009b). However, in 2009, the 
United States Preventative Task Force (USPSTF; 2010) released recommendations 
stating that women aged 50-74 should receive biennial mammography screenings and 
added that screenings prior to the age of 50 should be based on each individual patients 
risks and benefits of early screening (USPTF, 2010).  
In most cases mammography is viewed as the most accurate tool for screening, 
but this method may not be appropriate for young women who have denser breast tissue 
in comparison to their older counterparts. The accuracy of screening tests such as 
mammograms is measured in terms of both sensitivity and specificity. Sensitivity refers 
to the percentage of patients who receive positive breast cancer results from a diagnostic 
test among women with breast cancer. In respect to sensitivity, false positives occur when 
a patient receives a negative test result despite having the disease (NCI, 2010a). 
Specificity refers to the percentage of patients who receive a negative test result from a 
diagnostic test among patients who do not have the disease. In respect to specificity, false 
positives occur when patients receives a positive result although they do not have the 
disease (NCI, 2010c). 
A study of age-related accuracy of mammograms and ultrasounds found that 
mammography had a low sensitivity, detecting 76% of 25 cancers in women under the 





2003). A further study which investigated screening and diagnostic mammography use 
specifically in women under 40 found that both sensitivity and specificity varied across 
age groups as well as across diagnostic methods (Yankaskas et al., 2010). Screening 
mammography is a routine mammogram performed at a predesignated interval in time 
(i.e., yearly) when the patient does not present with any signs or symptoms, whereas 
diagnostic mammography is a mammogram performed when a women presents with 
clinical symptoms such as a lump or other symptoms of breast cancer (NCI, 2010c). 
Screening mammography in women aged 35-39 years (n = 73,335), sensitivity 
was 76.1% and specificity, 87.5%; in women aged 30-34 years (n = 10,527) sensitivity 
was 81.5% and specificity, 85.8%; in women aged 25-29 years (n = 2,282), sensitivity 
was 66.7% and specificity, 83.0%; and no cancers were detected in the women aged 18-
24 (n = 637). Diagnostic mammography in women aged 35-39 years had a sensitivity of 
82.5% and specificity of 88.9%; in women aged 30-34 years sensitivity was 86.3%, and 
specificity was 89.5%; in women aged 25-29 years sensitivity was 89.5%, and specificity 
was 88.4%; and in women aged 18-24 sensitivity was 100%, and specificity was 83.8%. 
The overall age-adjusted rates across all age groups were sensitivity, 85.7%; specificity, 
88.8%, positive predictive value (PPV) of 14.6%, and cancer detection rate of 14.3 
cancers per 1,000 mammograms (Yankaskas et al., 2010). 
Due to the recommended age guidelines and the aforementioned methods of 
screening, women under the age of 40 do not benefit from population screenings and 
commonly consult a physician when they are presenting with a palpable mass or other 





trials due to the lower incidence of breast cancer versus their older counterparts. In 
addition, there is a lack of literature and clinical research of breast cancer among women 
under 40 years of age when compared to their older counterparts. A basic keyword search 
of breast carcinoma and women or breast carcinoma and over 40 in PubMed yielded 
46,598 and 984 results respectively, whereas a basic search of the keywords breast 
carcinoma, and young women or breast carcinoma and under 40 yielded 251 and 228 
results respectively. To address this inadequacy within the literature, this study aimed to 
the discuss differences in prognostic characteristic within this population based on 
socioeconomic position. It has done so by evaluating differences in tumor size, tumor 
stage, and survival by socioeconomic position in women under 40 years of age upon 
primary diagnosis of breast cancer. Furthermore, the implications for social change 
include clearly defining formal screening guidelines for young women in higher-risk 
subgroups based on socioeconomic position.  
Purpose of the Study 
The purpose of this quantitative, retrospective, cohort study was to evaluate 
differences in tumor size, cancer stage, and survival by socioeconomic position in women 
under 40 years of age diagnosed with breast cancer. Current studies of breast cancer in 
young women have varied in the definition of young. being between 40 and 50 years of 
age; as a result there are conflicting results regarding stage upon diagnosis, course of 
treatment, and life expectancy (Anderson, Chu, & Devesa, 2004; Hall, Moorman, 
Millikan, & Newman, 2005; Swanson, Haslam, & Azzouz, 2003). Research has shown 





(Brinton, Sherman et al., 2008; Gajdos, Tartter, Bleiweiss, Bodian, & Brower, 2000; 
Yankaskas, 2006), and, in some cases, is considered a biologically different disease than 
that found in their older counterparts (Anders et al., 2008; Colleoni et al., 2007; Fisher et 
al., 2001; Fredholm et al., 2009; Rapiti et al., 2005). Other research has illustrated that 
breast cancer in young women is more aggressive based on the combined effects of 
familial history, genetic mutations, and hormonal responsiveness (Antoniou et al., 2003; 
Begg et al., 2008; Czene, Reilly, Hall, & Hartman, 2009; McAree et al., 2010). Breast 
cancer is also the leading cause of cancer related deaths among women ages 15 to 54 
(NCI, 2006a). This study addressed breast cancer among young women (under 40 years 
of age) in relation to differences in tumor size, cancer stage, and survival by 
socioeconomic position. 
Nature of the Study 
This study was a quantitative, retrospective, cohort study of newly diagnosed 
female breast cancer patients between the ages of 18 and 40. Participants were drawn 
from the SEER database (2009). More details about the SEER data are found in chapter 
3. The independent variable was socioeconomic position (SEP). Dependent variables 
included SEER summary stage, tumor size, and survival time. These variables were 
utilized to analyze differences in tumor size, cancer stage, and survival by socioeconomic 
position in women under 40 years of age diagnosed with breast cancer, the following 
research questions and hypotheses were utilized for this study.  
1. What is the independent effect of socioeconomic position on tumor size at the 





H0:. There is no association between socioeconomic position and tumor size at 
diagnosis. 
H1: There is an association between socioeconomic position and tumor size at 
diagnosis. 
2. What is the independent effect of socioeconomic position on the stage of 
cancer at the time of breast cancer diagnosis in women under 40? 
H0: There is no association between socioeconomic position and the stage of 
cancer at the time of breast cancer diagnosis in women under 40. 
H1: There is an association between socioeconomic position and the stage of 
cancer at the time of breast cancer diagnosis in women under 40. 
3. What is the independent effect of socioeconomic position on survival in 
women under 40 diagnosed with breast cancer?  
H0:There is no association between socioeconomic position and survival. 






The theoretical base for this study was driven by the association of the 
independent and dependent variables being investigated. The conceptual model shown in 
Figure 1 outlines the relationship between socioeconomic position, cancer stage, tumor 
size, and survival. In order to investigate if socioeconomic position has an effect on the 
biologic makeup of breast cancer in young women, variables such as tumor size and 




Figure 1. Study conceptual model. 
Although breast cancer is the most common type of cancer among women 
regardless of race or ethnicity, there are measureable disparities across these groups when 
looking at incidence, prevalence, and survival (Baquet et al., 2008; Brinton, Sherman et 
al., 2008; Hall et al., 2005; Joslyn, Foote, Nasseri, Coughlin, & Howe, 2005). African-





have been found to be strong indicators for decreased survival (Curtis, Quale, Haggstrom, 
& Smith-Bindman, 2008; Wong, Ettner, Boscardin, & Shapiro, 2009). The mortality rate 
of African-American women under the age of 35 is 3 times higher than that of age 
matched European-American women. Also, the age specific incidence rates among 
African-American women in this age group are more than twice the rate of European-
Americans (Shavers, Harlan, & Stevens, 2003). Along with race and ethnicity, another 
characteristic that has effect on breast cancer risk is socioeconomic status (SES). SES is 
also associated with access to care, age at diagnosis, and more aggressive tumor 
characteristics (Byers et al., 2008; Koh, 2009; O'Malley et al., 2003; Roetzheim et al., 
2000; Smith-Bindman et al., 2006; Wallington, Brawley, & Holmes, 2009; Watlington, 
Byers, Mouchawar, Sauaia, & Ellis, 2007).  
Another factor that may contribute to breast cancer risk is environmental 
exposures. Although it is not specifically known exactly how environmental exposures 
interact with genetic and hormonal factors, research has associations between certain 
organic solvents, and polycyclic aromatic hydrocarbons (PAHs) in occupational settings 
(Hansen, 1999). Identifying an association within population studies is more complex due 
to the lack of exposure assessment tools, latency, and variations in susceptibility.  
Definition of Terms 
Benign: Non cancerous - the majority of benign breast conditions are 
fibroadenomas, which are not considered to be cancer (ACS, 2009c). 
Biopsy: For the purpose of this study refers to the removal of cells or tissues from 





three main types of breast biopsies are: (a) incisional biopsy, where tissue is removed, (b) 
excisional biopsy, where an entire lump is removed, and (c) needle biopsy, where either 
fluid or tissue is removed for examination (NCI, 2010c). 
Breast density: Relates to different types of tissue present in the breast. Dense 
breasts are made up of more glandular and connective tissue rather than fat. Standard 
mammography films of dense breasts are more difficult to read in comparison to breasts 
that are less dense (NCI, 2010c).  
Chemotherapy: Treatment with drugs that kill cancer cells (NCI,2010c). 
Cyst: For the purpose of this study refers to a fluid filled sac or capsule within the 
breast (NCI, 2010c). 
Diagnostic mammogram: A mammogram performed when a women presents 
with clinical symptoms such as a lump or other symptoms of breast cancer (NCI, 2010c). 
Distant Cancer: A cancer which has spread from the primary tumor to distant 
tissue, lymph nodes or, organs. This is also referred to as distant metastasis (NCI, 2010c). 
Duct: A thin tube within the breast that carries milk from the breast lobules to the 
nipple; also called milk duct (NCI, 2010c). 
Estrogen: A hormone produced by the body that assists in developing and 
maintaining female sex characteristics. Lab-created estrogen is created for use in birth 
control medicine and to treat osteoporosis, side effects of menopause, and other 
menstrual disorders (NCI, 2010c). 
Lifetime risk: The probability of developing or dying from breast cancer during an 





Lobe: A portion of an organ, such as the breast (NCI, 2010c). 
Lumpectomy: A surgical procedure performed in order to remove abnormal tissue 
from the breast, as well as a small sample surrounding the area of concern. A 
lumpectomy is considered to be a type of breast conservation surgery (NCI, 2010c).  
Malignant: Cancerous; tumors which are malignant can invade and destroy 
surrounding tissue as well as spread to lymph nodes, distant tissue, and organs (NCI, 
2010c). 
Mammogram: An x-ray of the breast; a way to find breast cancers that are not 
palpable (NCI, 2010b). 
Magnetic resonance imaging (MRI): For the purpose of this study, an MRI is a 
breast cancer screening procedure used to differentiate between normal and diseased 
tissue within the breast. An MRI utilizes radio waves and a powerful magnet to obtain 
detailed images of the breast (NCI, 2010c) 
Mastectomy: A surgical procedure used to remove the breast, nipple, or as much 
of the breast tissue surrounding as necessary to eradicate cancerous tissue within the 
breast (NCI, 2010c) 
Older women: For the purpose of this study, women aged 40 or older. 
Prognosis: The potential outcome or course of breast cancer; expressed in the 
terms of course of treatment, chance of recovery or recurrence, and projected survival 
time (NCI, 2010b). 
Regional cancer: Breast cancer that has spread or grown beyond the primary 





Regional lymph node: A lymph node that drains lymphatic fluid from the region 
surrounding a tumor (NCI, 2010c). 
Screening mammography: A routine mammogram performed at a pre designated 
interval in time (i.e., yearly), when the patient does not present with any signs or 
symptoms (NCI, 2010c). 
SEER Summary Stage: Another system used to categorize cancer staging within 
the SEER registry. Summary staging is the most basic way of categorizing how far a 
cancer has spread from its point of origin. Cancer is staged as localized, regional or 
distant using this staging model. 
Sensitivity: For the purpose of this study refers to the percentage of patients who 
receive positive breast cancer results from a diagnostic test among women with breast 
cancer. False positives occur when a patient receives a negative test result despite having 
the disease (NCI, 2010a). 
Specificity: For the purpose of this study refers to the percentage of patients who 
receive a negative test result from a diagnostic test among patients who do not have the 
disease. False positives occur when patients receive a positive result although they do not 
have the disease (NCI, 2010c). 
Socioeconomic Position (SEP): Is comprised of measures including education 
attainment, income, and occupation (Galobardes, Lynch, & Smith, 2007). 
Socioeconomic status (SES): Comprised of measures such as geographic location, 
education, occupation, and income that may indicate specific health care choices, 





Staging: For the purpose of this study, refers to the extent of cancer within the 
body. It is based on tumor size, lymph node involvement, and whether the cancer has 
spread beyond the primary tumor to distant tissue, and organs (NCI, 2010b). 
Tumor: Abnormal cells combine to create a lump or mass within the breast, 
tumors can be either benign (non cancerous) or malignant (cancerous; NCI, 2010c). 
Younger women: For the purpose of this study, women under 40 years of age. 
Assumptions, Limitations, Scope and Delimitations of the Study 
For the purpose of the study, the SEER 17 registry was utilized. The study was 
based on one main assumption-that participating cancer registries followed the National 
Comprehensive Care Network cancer registry guidelines which standardized registry 
reporting as of 2000 (SEER, 2000). The SEER dataset has several limitations. Currently 
the SEER registry dataset is limited to 26% of the United States population. This 
coverage includes 23% of African-Americans, 23% of European-Americans, 40% of 
Hispanics, 42 % of American Indians and Alaska Natives, 53% of Asians, and 70% of 
Hawaiian/Pacific Islanders (SEER, 2000). The SEER program has a special focus on 
minority racial and ethnic groups as well as urban populations; this focus, in turn, equates 
to an overrepresentation of minorities within the data set. The overrepresentation of racial 
and ethnic groups within SEER is done to ensure sufficient population sizes for the 
purpose of statistical analysis. While the SEER dataset is limited to 26% of the 
population (see Figure 2), it does not account for patient migration. The concurrent 
migration of patients in and out of SEER registry counties can cause patients’ subsequent 





malignancy; however losing a patient to follow-up opportunities may influence 
calculations such as survival, which is dependent on long-term follow up of individual 
patients. 
 
Figure 2. Map of SEER Registry location coverage across the United States. 
Source is public domain, permission not required to reproduce: http://seer.cancer.gov/registries/ 
Another limitation of the dataset is the impact of Hurricanes Katrina and Rita on 
Louisiana's population from July-December 2005. Louisiana cases diagnosed during 
those 6 months were excluded from the limited-use database. Although the SEER 17 
registry does include one record for each of the 2,601,686 tumors diagnosed during this 
time period (July-December 2005), they are considered supplemental data (SEER, 2007). 
Cases for Louisiana in 2005 are only included in SEER's 1973-2007 research database if 





calculations, SEER excludes Louisiana cases diagnosed for the 6-month period, July-
December 2005. For all prevalence calculations, Louisiana cases are entirely excluded. 
Although each SEER research database includes a file for a Katrina/Rita Population 
Adjustment, these adjustments are only applicable to the SEER 17 Registries data, which 
includes the state of Louisiana. Within SEER 17, a separate dummy state was created that 
represents displaced individuals. It is labeled Hurricane Katrina/Rita Evacuees—
Populations Only—2005 and is included by default in rate calculations over the total U.S. 
population. As previously noted, there is no population adjustment for prevalence 
databases; therefore, Louisiana cases are entirely excluded during the identified 
timeframe.  
The design for this study was a non experimental in that the causal relationship 
between socioeconomic position, tumor size, cancer stage, and survival cannot be 
identified based upon the possible findings. The study was limited to assessing the 
potential effect of socioeconomic position on tumor size, cancer stage, and survival 
among women under 40 newly diagnosed with breast cancer. The study population was 
limited to women aged 18 to 39 years of age who received a primary diagnosis of breast 
cancer between the years of 2001-2006. The scope of this study was not to examine all 
identified risk factor associated with breast cancer. SEER does not collect data on health 
habits such as smoking, sedentary lifestyle, breast feeding behaviors, or obesity; 
therefore, these confounding factors were not controlled for during the data analysis, and 





Significance of the Study 
The significance of this study stems from the fact that breast cancer is the number 
one leading cause of death in women ages 15-54 (NCI, 2006a). Across all ages, breast 
cancer is the number one cause of cancer related deaths among Hispanic women and the 
second leading cause of cancer related deaths among European-American, African-
American, Asian/Pacific Islander, and American Indian/Alaska Native women (Centers 
for Disease Control and Prevention [CDC], 2010). There are inequalities in both clinical 
research and current literature pertaining to young women with breast cancer in 
comparison to their older counterparts. A basic keyword search of breast carcinoma and 
women or breast carcinoma and over 40 in PubMed yielded 46,598 and 984 results, 
respectively; whereas a basic search of the keywords breast carcinoma and young women 
or breast carcinoma and under 40 yielded 251 and 228 results, respectively. 
To address this inadequacy in the literature, this study aimed to explore 
differences in prognostic characteristic within this population based on socioeconomic 
position. It has done so by evaluating differences in tumor size, cancer stage, and survival 
by socioeconomic position in women under 40 years of age upon primary diagnosis of 
breast cancer. Furthermore, another implication for social change may include clearly 
defined formal screening guidelines for young women in higher-risk subgroups based on 
socioeconomic position.  
Summary 
Chapter 1 introduced the study and explained the background, assumptions, 





2 provides an overview of the current literature and research related to breast cancer in 
women under 40. It presents a discussion of the natural history of breast cancer, 
prevention and screening methods, clinical characteristics, and issues surrounding 
socioeconomic position within this population. Chapter 3 describes the research 
questions, research design, inclusion criteria, and data analysis. Chapter 4 presents the 





Chapter 2: Literature Review 
This chapter presents the different facets of breast cancer, including the basic 
definition, epidemiology, causation, and detection methods based on the current 
literature. The literature summarized in this chapter focuses on breast cancer among 
women under the age of 40 at the time of primary diagnosis. To understand the history of 
breast cancer as a disease and prognostic characteristics in relation to age, a compilation 
of journal articles was utilized. Medline, PubMed, NCI, and OVID databases were used.  
The search was limited to sources published between 1980 and 2010, and the 
following keywords were used: breast cancer, breast carcinoma, epidemiology, 
race/ethnicity, young women, premenopausal, morbidity, mortality, socioeconomic 
status, socioeconomic position, screening, environment, genetics, and prognostic 
characteristics. The majority of the literature operationally defines young women as those 
who are 50 years of age or younger; for the purpose of this study, the term referred to 
women under the age of 40. Within the current literature, it remains unclear whether the 
division at age 50 is due to a convenience of sample size breakdown (under 50, over 50) 
or the association with the initial mammography screening recommendations for women 
50 and older only. In other words, breast cancer among women 40 and under may 
possibly be a biologically different cancer in comparison to women over 40 years of age 
(Anders et al., 2008; Colleoni et al., 2007; Fisher et al., 2001; Fredholm et al., 2009; 
Rapiti et al., 2005). This difference in age categorization has further increased the gap in 





Because many studies define young women as being between 40 and 50 years of 
age, there are conflicting results regarding stage upon diagnosis, course of treatment, and 
life expectancy (Anderson et al., 2004; Hall et al., 2005; Swanson et al., 2003). Although 
these factors are difficult to compare due to varying age ranges and prognostic 
characteristics being investigated (Newman et al., 2002), this study focused on the 
evidence due to a biologically aggressive etiology (Anders et al., 2008; Colleoni et al., 
2007; Fisher et al., 2001; Fredholm et al., 2009; Rapiti et al., 2005) based on tumor size 
and stage. As previously noted, other research has illustrated that breast cancer in young 
women may be more aggressive in nature based on the combined effects of familial 
history, genetic mutations, and hormonal responsiveness (Antoniou et al., 2003; Begg et 
al., 2008; Czene et al., 2009; McAree et al., 2010). These individual factors, such as 
genetics and family history, are beyond the scope of this study. 
Anatomy of the Breast 
In order to comprehend the pathophysiology of breast cancer and overall breast 
health, it is beneficial to understand the basic anatomy of the breast. The breast is a 
glandular organ located on the chest, which is made up of connective tissue, fat, and 








Figure 3. A diagram of the anatomy of the normal breast.  
Note. Reprinted from ―Breast Cancer: What is Breast Cancer,‖ by The American Cancer Society, 2009, 
Breast Cancer: The Detailed Guide, p. 3. Source is public domain, no permission required. 
 
 
Figure 4. A diagram of the lymph (lymphatic) system of the breast.  
Note. Reprinted from ―Breast Cancer: What is Breast Cancer,‖ by The American Cancer Society, 2009b, 





History of Breast Cancer 
The mental and physical implications of a breast cancer diagnosis are vast 
regardless of the stage in which a woman is diagnosed (Deshields, Tibbs, Fan, & Taylor, 
2006; Kroenke et al., 2004; Sammarco, 2009). However, early detection can have a 
significant impact on a woman’s treatment and survival (Chan, Pintilie, Vallis, Girourd, 
& Goss, 2000; Lin et al., 2002; Newman et al., 2002).  
Numerous determinants contribute to this disease; some can be changed, and 
some cannot. Lifestyle choices such as not having children, taking hormone replacement 
therapy, abstaining from breastfeeding, consuming alcohol, being obese, eating high-fat 
diets, and having a sedentary lifestyle, can be changed. Determinants that cannot be 
changed include race, age, family cancer history, early menstruation, previous chest 
radiation, and genetics. Although various cosmetics and personal hygiene products are 
thought to be associated with breast cancer, to date there is no solid evidence linking 
personal products and breast cancer (Witorsch & Thomas, 2010). This area of concern 
warrants further research; therefore, it was not discussed in the context of this study. The 
aforementioned determinants are discussed in detail in chapter 2.  
Cancer occurs when abnormal cells grow at an uncharacteristic rate. These cells 
may also form into a lump or a mass called a tumor. If left undetected, these abnormal 
cells or tumors may spread to other areas of the body. Within the breast, there are 
different types of cancer; the most common types are ductal and lobular carcinoma 
(CDC, 2009). Breast cancer is defined by the American Cancer Society (ACS; 2009d) as 





that line the milk ducts; if the cancer has not spread beyond this area it is called ductal 
carcinoma in situ (DCIS). DCIS makes up approximately 85% of the in situ breast 
cancers diagnosed (ACS, 2009a). Ductal carcinoma can also spread beyond the ducts and 
into surrounding tissue; this type of cancer is called invasive ductal carcinoma.  
Lobular carcinoma (LCIS) begins in the breast lobe cells; the lobes, or lobules are 
the actual glands that produce milk within the milk ducts (CDC, 2009). Lobular 
carcinoma typically does not spread to the surrounding tissue except in cases of invasive 
lobular carcinoma. Another indicator of predisposition for breast cancer is called atypical 
hyperplasia. Atypical hyperplasia is a condition in which the cells of the breast appear 
abnormal and increased in number when inspected under a microscope (NCI, 2010c). 
Research has shown that women with biopsy confirmed atypical hyperplasia are 
approximately 5.3 times more likely to develop breast cancer compared to women with 
breast lesions that have not spread (Dupont & Page, 1985). 
A rare yet highly invasive form of breast cancer is inflammatory breast cancer 
(IBC). IBC makes up only 1-3% of breast cancers diagnosed within the United States 
(ACS, 2009c). This type of cancer tends to spread at a rapid rate and be diagnosed at a 
more advanced stage. Typically when IBC is diagnosed it is already advanced to Stage III 
cancer (ACS, 2009c). Unlike typical breast cancer, IBC does not form a lump that can be 
found during an exam. Instead, the breast appears to be red and inflamed and is warm to 
the touch; this coloring and inflammation is due to the cancer cells blocking the lymph 
vessels in the skin (NCI, 2006b). In addition to different presenting symptoms, IBC also 





of all other types of breast cancer occur more frequently in European-American women, 
IBC is 2 to 3 times more likely to occur among African-American women (NCI, 2006b). 
Another rare form of breast cancer is Paget disease, which affects the nipple. The 
cancer cells initially begin to form in the ducts but then spread to the skin of the nipple 
and areola. Paget disease accounts for approximately 1% of breast cancer; if caught in an 
early stage, the prognosis for survival can be excellent (NCI, 2006c). 
According to the NCI (2010a) in 2010, there will be an estimated 207,090 new 
cases diagnosed and 39,840 deaths among women that will be attributed to breast cancer. 
Additionally, the CDC (2010) reported that, with the exception of skin cancer, breast 
cancer is the most commonly diagnosed type of cancer among American women. It is 
also the leading cause of cancer death among Hispanic women, and the second leading 
cause of cancer related death among European-American, African-American, 
Asian/Pacific Islander, and American Indian/Alaska Native women.  
To understand the impact of a breast cancer diagnosis, it is necessary to 
understand the stages of breast cancer. Different stages are utilized in the diagnosis of 
breast cancer; these stage qualifications assist in planning a woman’s course of treatment. 
The National Breast Cancer Foundation (2009) defines the first stage of breast cancer as 
Stage 0, where atypical cells have not spread outside of the milk-producing organs (called 
ducts or lobules) into the surrounding breast tissue. This stage is referred to as carcinoma 
in situ, and it is classified into two different types. The first type is DCIS, early cancer 
which, if detected and treated, has a high survival rate. If DCIS is not detected and treated 





The second type is LCIS, which is not cancer itself, but rather an indicator that a woman 
has an increased risk of developing breast cancer in her lifetime. 
The second stage of breast cancer, called Stage I, refers to the early stage of 
invasive breast cancer. In Stage I breast cancer, the cancer is no larger than 2 centimeters 
and has not spread to beyond the breast to surrounding tissue or lymph nodes. The next 
stage of breast cancer is Stage II. Stage II breast cancer is classified into two types 
according to the size of the tumor and the level of lymph node involvement. In Stage II A 
breast cancer, the tumor is less than 2 centimeters and has spread to at least three lymph 
nodes. Tumors in Stage II A may be larger than 2 centimeters but no larger than 5 
centimeters and have not spread to surrounding lymph nodes. In Stage II B breast cancer, 
the tumor is between 2 and 5 centimeters and has spread to up to three lymph nodes. 
Tumors in Stage II B may also be larger than 5 centimeters but have not spread to the 
surrounding lymph nodes.  
The next stage of breast cancer is Stage III, which is also classified into two types 
according to the size of the tumor and the level of lymph node involvement. In Stage IIIA 
breast cancer, the tumor is larger than 2 centimeters but smaller than 5 centimeters and 
has spread to up to nine lymph nodes. In Stage III B breast cancer, the cancer has spread 
beyond the breast to surrounding tissues such as skin, chest wall, ribs, muscles, or lymph 
nodes within the chest wall or collarbone. The final stage of breast cancer is Stage IV. In 
Stage IV breast cancer, the cancer has spread beyond the breast to other organs and 





Although Stage 0 is noted as being precancerous, stages I and II are considered to 
be the early stages of developing breast cancer, Stage III is considered late-stage cancer, 
and Stage IV is advanced breast cancer. According to the American Joint Committee on 
Cancer (AJCC), there are three types of staging; clinical staging, pathologic staging, and 
restaging (American Joint Committee on Cancer, 2010). Clinical staging is used to 
determine how much cancer is in the body based on physical examination, imaging tests, 
and biopsies of affected areas (ACS, 2009c; AJCC, 2010). Clinical staging is performed 
at the time of diagnosis and assists in planning a woman’s course of treatment. Pathologic 
staging is performed following a procedure to extract tissue and combines clinical staging 
with the results from the surgical procedure (ACS, 2009c; AJCC, 2010). The pathological 
stage offers more precise information that can then be used to calculate possible 
treatment response and outcomes (prognosis). The final type of staging, called restaging, 
is not common. Restaging may be performed if the cancer reoccurs following the initial 
course of treatment (ACS, 2009c; AJCC, 2010). This type of staging would be done in 
order to reassess the current extent of the cancer and plan the appropriate course of 
treatment.  
Along with cancer staging itself, there are various systems or tools in place that 
assist medical professionals in the actual staging process. These systems aim to 
standardize cancer staging and reporting based on selected criteria. One of the most 
common systems to date was created by the AJCC and International Union Against 
Cancer (UICC; AJCC, 2010). The TNM Staging System is based on (T) the tumor size, 





Table 2  
TNM Staging Guidelines 
Stage T (tumor) N (lymph nodes) M (metastasis) 
Stage 0 Tis: Carcinoma in situ (DCIS, LCIS, 
or Paget disease of the nipple). 
N0: Cancer has not spread to nearby 
lymph nodes. 
M0: No distant 
metastases 
Stage 1 T1: Tumor size no larger than 2 
centimeters. 
N0: Cancer has not spread to nearby 
lymph nodes. 
M0: No distant 
metastases 
Stage 1B T0: No evidence of primary tumor. 
T1: Tumor size no larger than 2 
centimeters. 
N1mi: Micrometastases in 1 to 3 lymph 
nodes under the arm. 
M0: No distant 
metastases 
Stage 2A T0: No evidence of primary tumor. 




N1a: Cancer has spread to 1 to 3 lymph 
nodes under the arm sized greater than 2 
mm across. 
N1b: Cancer has spread to internal 
mammary lymph nodes.  
M0: No distant 
metastases 
 T2: Tumor is bigger than 2 centimeters 
but smaller than 5 centimeters. 
N0: Cancer has not spread to nearby 
lymph nodes. 
M0: No distant 
metastases 
Stage 2B T2: Tumor is bigger than 2 centimeters 
but smaller than 5 centimeters. 
 
OR 
N1: Cancer has spread to 1 to 3 axillary 
lymph nodes, and/or tiny amounts of 
cancer are found in internal mammary 
lymph nodes. 
M0: No distant 
metastases 
 T3: Tumor is more than 5 cm across. N0: Cancer has not spread to nearby 
lymph nodes. 
M0: No distant 
metastases 
Stage 3A T2: Tumor is bigger than 2 centimeters 
but smaller than 5 centimeters. 
 
OR 
N2: Cancer has spread to 4 to 9 lymph 
nodes under the arm, or has enlarged the 
internal mammary lymph nodes. 
M0: No distant 
metastases 
 T3: Tumor is more than 5 cm across. N1: Cancer has spread to 1 to 3 axillary 
lymph nodes, and/or tiny amounts of 
cancer are found in internal mammary 
lymph nodes. 
N2: Cancer has spread to 4 to 9 lymph 
nodes or has enlarged the internal 
mammary lymph nodes. 
M0: No distant 
metastases 
Stage 3B T4: Tumor of any size growing into 
the chest wall or skin. This includes 
inflammatory breast cancer. 
Any N: Cancer may or may not have 
spread to nearby lymph nodes. 
M0: No distant 
metastases  
Stage 3C Any T: The tumor is any size. N3: Cancer has spread to 10 or more 
axillary lymph nodes, under or over the 
collar bone, or has enlarged the internal 
mammary lymph nodes.  
M0: No distant 
metastases  
Stage 4 Any T: The tumor is any size. Any N: Cancer may or may not have 
spread to the lymph nodes. 
M1: Distant 
metastases 
Unstaged TX: Primary tumor cannot be 
evaluated. 





Note. Adapted from ―How is breast cancer staged? A detailed guide to breast cancer staging,‖ American 
Cancer Society, 2010, Source is public domain, permission not required to reproduce; and ―Cancer 






Another system used to categorize cancer staging within SEER is called SEER 
Summary Staging. Summary staging is the most basic way of categorizing how far a 
cancer has spread from its point of origin. The 2000 version of the Summary Stage 
Manual, which was used in this study, encompasses all of information submitted to the 
registry and is a combination of the most precise clinical and pathological documentation 
of the extent of disease (SEER, 2000). 
SEER describes cancer in five stages: in situ, localized, regional, distant, and 
uncategorized. In situ cancer is early cancer that is present only in the layer of cells in 
which it began, and would encompass Stage 0 cancers. Localized cancer that is restricted 
to the site of origin without evidence of spreading would encompass Stage I cancer. 
Regional cancer that has grown beyond the original (primary) tumor to nearby lymph 
nodes or organs and tissues would encompass Stage II cancer. Distant stage cancer refers 
to cancer that has spread from the original (primary) tumor to distant organs or distant 
lymph nodes; this includes stages III and IV. Unstaged refers to cancers for which there is 
not enough information to indicate a stage (SEER, 2010). Previous studies have 
suggested that the highest proportions of unstaged cancer cases are among the elderly, 
minority populations, and those living in rural areas (Worthington, Koroukian, & Cooper, 
2008).  
Worthington et al. (2008) examined the characteristics of unstaged colon and 
rectal cancer cases to identify which stage components were missing, and to characterize 
and identify predictors of unstaged cancer. The population was comprised of 128,418 





which staging components were missing, including tumor size (T), number of lymph 
nodes (N), and metastases (M). The stage component M was missing most frequently 
across both age and cancer groups. Worthington et al. attribute this finding to the patients 
possible refusal to undergo diagnostic testing, the discovery of an inoperable tumor, 
being treated with endoscopic therapy, or receiving treatment outside of the SEER 
reporting area (2008). Identified predictors for having unstaged cancer were African-
American descent and advanced age (65 years or older; Worthington et al., 2008).  
Klassen et al. (2006) analyzed missing prostate stage and grade data in Maryland, 
and the potential effects on research and policy. Prostate Cancer Surveillance Data were 
obtained from the Maryland Cancer Registry (N = 22,217), logistic regression was then 
used to examine potential patterns across demographic and socioeconomic variables. The 
researchers looked at both missing stage and grade individually. Older age (65-74 and 75-
106), African-American race, missing grade, and a higher county-level median income 
increased the probability of missing stage. While having a more recent diagnosis, higher 
blockgroup-level median income, and living in a rural county decreased the probability of 
missing stage. When looking at factors influencing missing tumor grade, older age, 
missing or later stage, and a higher blockgroup-level median income increased the 
probability of missing tumor grade. Whereas having a more recent diagnosis, higher 
county-level median income, and living in a rural county decreased the likelihood of 
missing tumor grade.  
Although there was no noted difference in the proportion of unstaged cases across 





(84% vs. 86%, p = 0.007; Klassen et al., 2006). The proportions of both unstaged and 
ungraded tumors increase with decreasing income, however, it is noted that despite the 
positive association between the two (Pearson correlation coefficient r = 0.32), they are 
influenced by different factors (Klassen et al., 2006). Klassen et al. (2006) found that the 
absence of staging (OR, 4.55), increased age (OR, 1.12), the ratio of urologists to patients 
(OR, 1.13), and later stage (OR, 1.16), were significant predictors of ungraded tumors. 
Significant predictors of ungraded tumors were missing grade (OR, 4.73) increased age 
(OR, 1.98), and African-American race (OR, 1.12; Klassen et al., 2006). 
Incidence and Mortality Trends 
Breast cancer incidence and mortality rates have increased over time which can be 
attributed to a range of lifestyle and healthcare behaviors. According to a collaborative 
report from ACS, CDC, NCI, and the North American Association of Central Cancer 
Registries (NAACCR; Edwards et al., 2010) there have been five distinct phases in breast 
cancer incidence trends since 1975: (a) between 1975 and 1980, incidence was constant; 
(b) between 1980 and 1987, incidence increased by 4.0% per year; (c) between 1987 and 
1994, incidence was constant, (d) between 1994 and 1999, incidence rates increased by 
1.6% per year; and (e) between 1999 and 2006, incidence rates decreased by 2.0% per 
year, except among Asian American/Pacific Islander women. Also, during 1997-2006 
there was a slight decrease in breast cancer related death rates among European-
American; African-American and Hispanic women (Edwards et al., 2010). Figure 5 
represents these trends among specific racial/ethnic groups during this time period (1975-





entire period of time; however, specific data were not available within SEER for 
Hispanic, Asian American/Pacific Islander, and American Indian/Alaska Native women 
until 1992.  
Slight increases and decreases in incidence rates can be due to lifestyle choices 
such as a shift in reproductive patterns (Sweeny et al., 2008; Ursin et al., 2004), increased 
obesity rates (Brody et al., 2007; Daling et al., 2001; Reeves et al., 2007), and the use of 
menopausal hormone replacement therapy (Brinton et al., 2008; Lacey et al., 2009). The 
large increase noted between 1980 and 1987 (4.0% per year) is due to an increased use of 
mammography in population screenings (Garfinkel, Boring, & Heath, 1994). During 
these years, incidence rates of smaller tumors (2.0 cm or less) more than doubled, while 
rates of larger tumors (3.0 cm or more) decreased 27% (Garfinkel et al., 1994). It is noted 
that a sharp decrease in incidence rates (2.0% per year) between 2002 and 2003 in 
women aged 50-69 was attributed to a rapid drop in hormone use following lower usage 
of combined hormone replacement therapy (Edwards et al., 2010). The slight decrease 
noted around the year 2000 may be related to a reported decrease or stabilization in 
mammography use in women over 40. Also, the slight decline noted in 2000 can be 
attributed to the lower prevalence of mammography use (Breen et al., 2007; Miller, King, 
Ryerson, Eheman, & White, 2009; Ryerson, Miller, Eheman, Leadbetter, & White, 
2008). The slight decline noted, gives the appearance of a continued decline in incidence 
rates, whereas it actuality it reflects the under diagnosis or delayed diagnosis, and is not a 





Trends in breast cancer incidence and mortality across racial/ethnic groups have 
also been noted. Incidence and prevalence data for African-American and European-
American women are readily available since the year 1973 within SEER; at that time race 
was categorized into White, Black, and Other. The Other race category used includes 
American Indian/Alaska Native and Asian/Pacific Islander’s combined (SEER, 2009). 
After 1992, SEER categorized race into four groups: White, Black, American 
Indian/Alaska Native, Asian/Pacific Islander, and Hispanic origin. Figures 4 and 5 
illustrate trends in both incidence and death rates by race and ethnicity between 1975 and 
2006 in the United States. Between the early 1970s and 1987, breast cancer incidence 
increased rapidly for both African-American and European-American women. This rapid 







Figure 5. Trends in female breast cancer incidence rates* by race and ethnicity, U.S., 1975-2006. 
Data Source: Rates are per 100,000 and are age-adjusted to the 2000 U.S. Std Population. Cancer sites 
include invasive cases only unless otherwise noted. Mortality source: U.S. Mortality Files, National Center 
for Health Statistics, CDC. Incidence source: Data for African-Americans and European-Americans are 
from the SEER 9 registries, data for Asian/Pacific Islander, Hispanic, and American Indian/Alaska Native 
are from the SEER 13 registries. Hispanics and Non Hispanics are not mutually exclusive from whites, 
blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and 
Non Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Rates for American 
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Figure 6. Age-specific (crude) SEER incidence rates by race/ethnicity female breast all ages 2000-2007. 
Data Source: Rates are per 100,000 and are age-adjusted to the 2000 U.S. Standard Population. Cancer sites 
include invasive cases only unless otherwise noted. Mortality source: U.S. Mortality Files, National Center 
for Health Statistics, CDC. Incidence source: Data for African-Americans and European-Americans are 
from the SEER 9 registries, data for Asian/Pacific Islander, Hispanic, and American Indian/Alaska Native 
are from the SEER 13 registries. Hispanics and Non Hispanics are not mutually exclusive from whites, 
blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and 
Non Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Rates for American 



















Figure 7. Trends in female breast cancer death rates by race and ethnicity, U.S., 1975-2006. 
 
Data Source: Rates are per 100,000 and are age-adjusted to the 2000 U.S. Std Population. Cancer sites 
include invasive cases only unless otherwise noted. Mortality source: U.S. Mortality Files, National Center 
for Health Statistics, CDC. Incidence source: Data for African-Americans and European-Americans are 
from the SEER 9 registries, data for Asian/Pacific Islander, Hispanic, and American Indian/Alaska Native 
are from the SEER 13 registries. Hispanics and Non Hispanics are not mutually exclusive from whites, 
blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and 
Non Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Rates for American 
Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties. 
Breast Cancer in Young Women 
Between 2001-2006 the median age of women newly diagnosed with breast 
cancer was 61; women under 40 accounted for approximately 6% of newly diagnosed 
cases (Horner et al., 2009), and women over 40 years of age accounted for approximately 
95% of newly diagnosed cases (ACS, 2010a). 
Although the occurrence of breast cancer in women under 40 is somewhat rare, 
this group tends to present with cancer that is more advanced along with poorer 
prognostic characteristics (Yankaskas, 2006). As shown in Table 3, young women were 
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counterparts. The 5-year relative survival rate is slightly lower among women diagnosed 
with breast cancer before age 40 (83%) compared to women diagnosed at ages 40 or 
older (90%; ACS, 2010a). The same factors that put older women at an increased risk of 
cancer also effect young women. These factors include family history, African-American 
race, lack of physical activity, later age at menarche, genetic factors, and later age at first 
birth (Anders et al., 2008; Baquet et al., 2008; Yankaskas, 2006). Risk factors specifically 
associated with young women include genetics, oral contraceptive use, multiparity, 
history of miscarriages, smoking, and treatment for Hodgkin’s Lymphoma (Althuis et al., 
2003; Hall et al., 2005; Yankaskas, 2006). 
Table 3  
Stage Distribution (SEER Summary Stage 2000) percent by Age at Diagnosis/Death, 













Age  Age  Age  Age 
Stage at Diagnosis <50 50+  <50 50+  <50 50+  <50 50+ 
Localized 54.8 64.3  47.0 53.7  50.8 61.6  56.6 65.0 
Regional 39.8 28.3  43.6 34.3  40.0 29.7  38.7 28.9 
Distant 3.8 4.7  6.9 8.7  6.3 6.2  3.6 4.4 
Unstaged 1.6 2.8  2.4 3.4  2.9 2.5  1.2 1.7 
Data Source: Based on the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New 
Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia 
and California, excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey). California excluding 
SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2006. The 
remaining 13 SEER Areas contribute cases for the entire period 1999-2006. Based on follow-up of patients 







Overall, breast cancer incidence and death rates increase with age. During the 
years 2002-2006, approximately 95% of new cases and 97% of cancer deaths were 
among women aged 40 or older (Copeland et al., 2010). After the age of 80, there is a 
decrease in incidence rates. This decrease may reflect lower incidence of population 
screenings, detection of cancers before age 80, and/or incomplete detection (ACS, 
2010a). 
Prevention and Screening 
There are many different risks associated with breast cancer; some can be 
changed and some cannot. Determinants that cannot be changed include race, age, family 
cancer history, early menstruation, previous chest radiation, and genetics (BRCA1 or 
BRCA2 mutations). Lifestyle choices that can also increase the risk are the use of oral 
contraceptives, not having children, taking hormone replacement therapy, abstaining 
from breastfeeding, consuming alcohol, being obese, eating high-fat diets, and having a 
sedentary lifestyle. 
Although breast cancer is the most common type of cancer among women 
regardless of race or ethnicity (ACS, 2010a), and is the leading cause of cancer related 
deaths among women aged 15-54 (NCI, 2006a), there continues to be contrasting 
information regarding breast cancer among young women (YSC, 2008). Until recently, 
women were typically encouraged to begin breast self-exams (BSE) at age 20; and yearly 
mammograms at age 40. However, in 2009, the United States Preventative Task Force 
(USPTF) released recommendations stating that women aged 50-74 should receive 





should be based on each individual patients risks and benefits of early screening (U.S. 
Preventive Services Task Force [USPSTF], 2010).  
Conversely, according the ACS (2009c), women who are considered to be at a 
higher risk of breast cancer (greater than 20% lifetime risk) should include yearly breast 
MRIs beginning at the age of 30. Lifetime risk, which is the probability of developing or 
dying from breast cancer during an individual’s lifetime; can be calculated using risk 
assessment tools such as the Breast Cancer Risk Assessment Tool, which is based on the 
Gail Model (Gail et al., 1989), and is discussed below. Also, women in this age group do 
not benefit from population screenings as only a small percentage of the population is 
affected by this cancer, and the mammography technology does not detect tumors in 
young breast tissue due to its density. The overall age adjusted PPV of screening 
mammography within this age group is 1.3%, and the age adjusted PPV of diagnostic 
mammography is 14.6% (Houssami et al., 2003). 
Weiss et al. (1996) performed a population based case control study among 
women aged 20-44, who were newly diagnosed with breast cancer between 1990 and 
1992, within the SEER registries of Atlanta, Seattle, and New Jersey. Control subjects 
were chosen through random digit dialing and matched by geographic location. A total of 
1.616 breast cancers were analyzed. The method of detection among this population 
varied across stage of disease and age (see Table 4), however, the most common method 
of detection in all age groups was detection by the woman herself, or by her partner 





Table 4  
Method of Detection of Breast Cancer by Age and Stage at Diagnosis 
 Stage at Diagnosisa 
 
InSitu  
(n = 214) 
Local 
(n = 784) 
Regional/Distant 
(n = 602) 
Total 
(n = 1600) 
Method of Detection n % n % n % n % 

















































































































Data on methods of detection were not available for 14 in situ cases and two regional/distant cases. 
b
Includes breast self-examination and accidental discovery by the patient or by her partner. 
c
Includes pain, 
infection, mastitis, swelling, dimpling and nipple discharge, or bleeding. Adapted from ―Epidemiology of in 
situ and invasive breast cancer in women aged under 45,‖ Weiss, H. A., Brinton, L. A., Brogan, D., Coates, 
R. J., Gammon, M. D., Malone, K. E., Schoenberg, J. B., & Swanson, C. A.,  1996, British Journal of 
Cancer, 73, p. 1298-1305. Copyright 1996 Stockton Press. Adapted with permission. 
Currently, no uniform guidelines exist concerning screening procedures for 
women under the age of 40 who are at an elevated risk. Additionally, cancer risk 
assessment tools such as the Breast Cancer Risk Assessment Tool, which is based on the 
Gail Model (Gail et al., 1989) are designed to estimate the lifetime risk for women aged 
35 or older, and have been found to be ineffective to estimate risk in young women 





The Gail model calculates both a 5-year and lifetime risk estimation for developing breast 
cancer. This calculation is based on the current age, race/ethnicity, age at menarche, age 
at the first live birth of a child, number of biopsies, and breast cancer history amongst 
first degree relatives (Gail et al., 1989). Although the Gail Model has been validated for 
European-American women, it has been found to underestimate risk among African-
American women (Gail et al., 2007), and has not been thoroughly validated in Hispanic, 
Asian, or American Indian/Alaska Native women (Kaur, Roubidoux, Sloan, & Novotny, 
2004). In 2007, the CARE model was created in order to more thoroughly ascertain risk 
among African-American women. The CARE model was structured around the original 
the Gail model constructs, and was based on updated incidence and mortality data among 
African-American women (Gail et al., 2007).  
Consequently, it is essential for women to understand their actual breast cancer 
risk in order to have an open discussion with their doctor about proper screening methods 
based on this risk. In most cases mammography is viewed as the most accurate tool for 
screening in older women, but this method may not be appropriate for young women who 
have denser breast tissue in comparison to their older counterparts. A study on age-
related accuracy of mammographies and ultrasounds found that mammography had a low 
sensitivity, detecting 76% of 25 cancers in women under the age of 35 and 69% of 
cancers in women between the ages of 36 and 40 (Houssami et al., 2003). When 
ultrasounds were utilized in the presence of a palpable mass, however, sensitivity 
increased to 84% for women under the age of 40 (Houssami et al., 2003). The overall age 





increased with age 1.0% in women aged 25-29, 1.5% in women aged 30-34, and 1.3% in 
women aged 35-39. When looking at the overall age adjusted PPV of diagnostic 
mammograms (PPV 14.6%), there was a more pronounced increase with age. In women 
aged 18-24 the PPV was 2.3%, 8% in women aged 25-29, 13.8% in women aged 30-34, 
and 18.6% in women aged 35-39 (Houssami et al., 2003).  
An additional study which investigated screening and diagnostic mammography 
use specifically in women under 40, found that both sensitivity and specificity varied 
across age groups as well as across diagnostic methods (Yankaskas et al., 2010). 
Screening mammography in women aged 35-39 years (n = 73,335) sensitivity was 76.1% 
and specificity was 87.5%; in women aged 30-34 years (n = 10,527) sensitivity was 
81.5% and specificity was 85.8%, in women aged 25-29 years (n = 2,282) sensitivity was 
66.7% and specificity was 83.0%; and no cancers were detected in the women aged 18-24 
(n = 637). Diagnostic mammography in women aged 35-39 years had a sensitivity was 
82.5% and specificity was 88.9%; in women aged 30-34 years sensitivity was 86.3% and 
specificity was 89.5%, in women aged 25-29 years sensitivity was 89.5% and specificity 
was 88.4%; and in women aged 18-24 sensitivity was 100% and specificity was 83.8%. 
The overall age-adjusted rates across all age groups were: sensitivity of 85.7%, 
specificity of 88.8%, PPV of 14.6%, and cancer detection rate of 14.3 cancers per 1000 
mammograms (Yankaskas et al., 2010). 
The researchers found that although younger women have very low breast cancer 
rates, their recall rates to receive additional screenings were high. This high recall rate 





mask tumors, as well as contribute to the lower performance of mammography in young 
women overall (see Table 5). 
Table 5  
Characteristics of Young Women Having Their First Mammography, Either Screening or 
Diagnostic, at Ages 18-39 Years: Breast Cancer Surveillance Consortium 
 Screening Mammography  Diagnostic Mammography 
Characteristics 
Mammograms 
 No. (%) 
Cancers 
 No. (%)  
Mammograms 
 No. (%) 
Cancers 
 No. (%) 
Total 86781  188   30956  526 
Age Group      
18-24  637 (0.7)  0 (0.0)   1552 (5.0)  5 (1.0) 
25-29  2282 (2.6)  6 (3.2)   4240 (13.7)  38 (7.2) 
30-34 10527 (12.1)  27 (14.4)   11361 (36.7)  168 (31.9) 
35-39 73335 (84.5)  155 (82.4)   13803 (44.6)  315 (59.9) 
Race      
White 58137 (67.0)  121 (64.4)   20726 (66.0)  345 (65.6) 
African-American  5994 (6.9)  22 (11.7)   2604 (8.4)  72 (13.7) 
Other 13910 (16.0)  21 (11.2)   4746 (15.3)  71 (13.5) 
Missing  8740 (10.1)  24 (12.8)   2880 (9.3)  38 (7.2) 
Breast Density      
Almost entirely fat  3069 (3.5)  3 (1.6)   1012 (3.3)  9 (1.7) 
Scattered fibroglandular 
densities 20172 (23.2)  41 (21.8)   6413 (20.7)  92 (17.5) 
Heterogeneously dense 26837 (30.9)  70 (37.2)   10193 (32.9)  194 (36.9) 
Extremely dense  8957 (10.3)  22 (11.7)   4596 (14.8)  80 (15.2) 
Missing 27746 (32.0)  52 (27.7)   8742 (28.2)  151 (28.7) 
Self-reported breast lump      
Yes  4302 (5.0)  49 (26.1)   20392 (65.9)  455 (86.5) 
No 78924 (90.9)  127 (67.5)   8884 (28.7)  61 (11.6) 
Missing  3555 (4.1)  12 (6.4)   1680 (5.4)  10 (1.9) 
Note. Adapted from ―Performance of first mammography examination in women younger than 40 Years,‖ 
Yankaskas, B., Haneuse, S., Kapp, J. M., Kerlikowske, K., Geller, B., & Buist, D., 2010, Journal of the 





Although breast cancer screenings are necessary to confirm the presence of 
cancer, there are noted limitations and risks such as false negatives, false positives, and 
radiation exposure. False negatives occur when mammograms appear normal, but miss 
breast cancer that is present at the time of the screening, whereas false positives occur 
when a mammogram appears to be abnormal when there is no actual cancer present at the 
time of screening. Houssami et al. (2003) found that among the women in their study that 
did not have cancer, approximately 9% received one true-negative result, while the 
opposite test (mammography or sonography) produced a false-positive. 
As discussed above, these limitations can occur in women that have dense breasts 
in which mammography has been shown to have lower sensitivity (Houssami et al., 2003; 
Yankaskas et al., 2010). Similarly, false positives can occur when a mammogram is 
deemed to be abnormal, when in fact no breast cancer is present at the time of the 
screening. As previously mentioned, the overall age adjusted positive predictive value 
(PPV) of screening mammography was 1.3%, the PPV increased with age 1.0% in 
women aged 25-29, 1.5% in women aged 30-34, and 1.3% in women aged 35-39 
(Houssami et al., 2003). The low PPVs among this population due to issues such as breast 
density (Tamimi, Byrne, Colditz, & Hankinson, 2007) may potentially lead to 
unnecessary biopsies and testing in women (Yankaskas et al., 2010). 
A possible risk associated with mammography is radiation exposure. 
Mammograms use very low levels of radiation; although it is not definitively known, 
contradictory reports discuss repeated low-dose medical radiation exposure and breast 





Another noted issue linked to screening is interval cancer. Interval cancer is 
cancer that occurs in the time period between screening tests such as between 
recommended annual mammograms. Interval cancers have a tendency to be larger, and 
have a higher grade and stage at the time of diagnosis in comparison to cancers that are 
detected at an initial screening. This suggests that interval cancers may be biologically 
different and more aggressive than screen-detected cancers (Raja, Hubbard, & Salman, 
2001). Lowery et al. (2011) utilized a population-based mammography program in 
Colorado (1994-2001) to examine the risk factors for interval breast cancer among 
women. The overall risk for interval cancer was analyzed in terms of the incidence per 
10,000 negative screenings and the proportion of all breast cancers positively diagnosed. 
Among the 208,667 women aged 40 and older that were screened, the researchers 
identified both interval (N = 557) and screen-detected cancers (N = 1,545; Lowery et al., 
2011). Lowery also noted that the risk of interval cancer was 29.5 per 10,000 women 
screened.  
Lowery et al. (2011) investigated interval cancer by calculating both the incidence 
per 10,000 normal mammograms and the proportion of interval versus screen-detected 
cancers diagnosed among all women screened. The authors speculate that by assessing 
risk using a dual approach, it may assist in defining variables that are important in 
calculating risk based on etiology as well as identifying women that are high-risk and 
would benefit from increased surveillance in-between regular screenings (Lowery et al., 
2011). The researchers found that incidence rates were elevated for women >50 (OR, 





3.84), and women who had used or were currently using hormones (OR, 1.54; see Table 
6). Hispanic women had lower incidence than European-Americans (OR, 0.52). Overall, 
interval cancers represented 26% of all newly diagnosed cancers. This proportion was 
higher in women <50 (OR, 1.41) and in women with dense breasts (OR, 2.95; Lowery et 
al., 2011). Extreme breast density was found to predict more than a threefold increase in 
incidence of interval cancer in both younger women (OR, 3.66) and older women (OR, 
3.79). Density also disproportionately predicted occurrence of interval versus screen-
detected cancer but only in older women (OR, 3.53; Lowery et al., 2011). 
The researchers note that there was not a significant difference in proportion of 
interval cancer identified across racial and ethnic groups. Although there was a somewhat 
increased proportion of breast cancers diagnosed in African-American women when 
compared to European-American women (31% vs. 27%), this was not found to be 
significant (Lowery et al., 2011). 
The researchers conclude that the incidence of interval cancer tends to increase 
with age, breast density, hormone use, and family history. Based on these findings, 
efforts to reduce the occurrence of interval cancers among these subgroups of women 
should be made. The increased proportion of interval cancers associated with young age 
and breast density indicate that interval cancers result from difficulties in detection due to 
dense breasts and rapid growth of the cancer itself. Women within the identified high-risk 
subgroups may benefit from more intense screening and from tailored breast health 





Table 6  
Risk of Interval Versus Screen-detected Breast Cancer According to Age, Ethnicity, 
Family History, Current Hormone Use, and Breast Density Within 12 Months of a 
Screening Mammogram 
Characteristic 
Number of interval 
breast cancers 
 N (%) 
Number of screen-
detected cancers 
 N (%) 
Odds ratio-interval 
vs. screen-detected 
 crude (95% CI) 
Odds ratio adjusted 
(95% CI) 
Total  557 (26%)  1,545 (74%)   
Age     
40-49   125 (33%)   256 (66%)  1.58 (1.19-2.10)  1.41 (1.04-1.90) 
50-59   160 (27%)  432 (78%)  1.20 (0.92-1.55)  1.04 (0.79-1.37) 
60-69   130 (25%)  398 (75%)  1.06 (0.80-1.39)  0.95 (0.72-1.26) 
70+   142 (24%)  459 (76%)  1.00  1.00 
Ethnicity     
African-American   17 (31%)  37 (69%)  1.27 (0.71-2.27)  1.24 (0.68-2.26) 
Hispanic   21 (20%)  83 (80%)  0.70 (0.43-1.14)  0.70 (0.43-1.15) 
Non Hispanic White   508 (27%)  1,400 (73%)  1.00  1.00 
Family History     
FDR* dx<50   19 (37%)  32 (63%)  1.75 (0.98-3.13)  1.70 (0.94-3.06) 
FDR* (any age)   150 (30%)  343 (70%)  1.29 (1.03-1.61)  1.24 (0.98-1.56) 
No Family Hx  407 (25%)  1,202 (75%)  1.00  1.00 
Current Hormones     
Yes  150 (27%)  398 (73%)  1.36 (1.02-1.80)  1.32 (0.99-1.76) 
No  111 (22%)   400 (78%)  1.00  1.00 
Breast Density     
Extremely dense   54 (43%)  71 (57%)  3.31 (2.20-4.97)  2.95 (1.94-4.48) 
Heterogeneous dense   183 (32%)  394 (67%)  2.02 (1.54-2.64)  1.87 (1.42-2.46) 
Entirely fat/ scattered 
fibrodensities  
 113 (19%)  491 (81%)  1.00  1.00 
Note. *FDR = First Degree Relative. Adapted from ―Complementary approaches to assessing risk factors 
for interval breast cancer,‖ J. Lowery et al., 2011, Cancer Causes and Control, 22, p. 23-31. Copyright 
2010 by Springer Science Media. Adapted with permission. 
 
Health Behavior Risks 
Numerous determinants contribute to this disease; some can be changed, and 





therapy, abstaining from breastfeeding, consuming alcohol, being obese, eating high-fat 
diets, and having a sedentary lifestyle, can be changed. 
Smoking 
The link between smoking and breast cancer has been highly debated in the 
literature among both young and older women (Ahern, Lash, Egan, & Baron, 2009; Band, 
Le, Fang, & Deschamps, 2002; Hamajima et al., 2002). Multiple studies have found no 
significant association between smoking and breast cancer risk (Al-Delaimy, Cho, Chen, 
Colditz, & Willet, 2004; Lash &Aschengrau, 2002; Prescott, Ma, Bernstein, & Ursin, 
2007), whereas multiple studies have identified an increased risk (Band et al., 2002; 
Kropp & Chang-Claude, 2002; Palmer et al., 1991).  
Al-Delaimy et al. (2004) followed a group of 112,844 women, most of which 
were premenopausal aged 25-42. The women were followed for 10 years to investigate 
the possible association between smoking and breast cancer incidence based on estrogen 
receptor status. During the course of follow-up, there were 1,009 cases of breast cancer 
diagnosed (Al-Delaimy et al., 2004). However, the Al-Delaimy et al. (2004) found no 
significant increase in overall breast cancer risk associated with smoking status, as the 
relative risk for never smokers was (RR, 1.00), past smokers (RR, 1.18), and current 
smokers (RR, 1.12). Covariates included age, BMI, height, alcohol consumption, age at 
menarche, use of oral contraceptives, age at first live birth, parity, personal history of 
benign breast disease, family history of breast cancer, and menopause status (Al-Delaimy 





In contrast to the findings of Al-Delaimy et al. (2004), Gram et al. (2005) 
followed a similarly aged group of women with the opposite result. A group of 102,098 
women, ages 30-50, were observed over a time period of 8 years. During the course of 
the study, 1,240 women were diagnosed with breast cancer (Gram et al., 2005). 
Covariates included age at enrollment, age at menarche, menopause status, age at first 
live birth, parity, BMI, alcohol consumption, use of oral contraceptives, and family 
history of breast cancer (Gram et al., 2005). Non smoking women were utilized as the 
comparison group (RR, 1.0), an increased risk was identified among women who had 
smoked for at least 20 years, and over 10 cigarettes per day (RR, 1.34), women who 
began smoking prior to their first live birth (RR, 1.27), women who began smoking prior 
to menarche (RR, 1.39), and women who began smoking before age 15 (RR, 1.48; Gram 
et al., 2005). This same increase in risk however, was not noted in women who had 
smoked for at least 20 years following their first live birth. Another important finding 
from this cohort was that the researchers did not find that family history of breast cancer, 
menopause status, or any other previously established risk factor for breast cancer 
modified the association found with smoking (Gram et al., 2005). 
Breast feeding 
The protective effects of breast feeding in reducing breast cancer risk has been 
observed among women of all ages and ethnicities (Ursin et al., 2005). There are multiple 
mechanisms which are thought to be associated with this protective effect against breast 
cancer; postponing ovulation, decreasing estrogen levels in the breast, changing the 





postpones ovulation, which in turn reduces the fluctuation of hormones throughout each 
menstrual cycle (Russo & Russo, 1994; Ursin et al., 2005). The composition of breast 
tissue changes across a woman’s pregnancy, these changes can lead to permanent 
physiological changes within the breast which are thought to offer a protective effect 
against breast cancer (Petrakis et al., 1987; Russo & Russo, 1994; Ursin et al., 2005). 
Ursin et al. (2004) evaluated if the number of full-term pregnancies, a woman’s 
age at first full-term pregnancy, and total duration of breastfeeding were associated with 
comparable relative risk across both European-American and African-American women. 
The study population was comprised of 4,567 women (2,950 European-American 
women and 1,617 African-American women) 35-64 years old, who had been newly 
diagnosed with invasive breast cancer between 1994 and 1998. The control participants 
included 4,668 women (3,012 European-American women and 1,656 African-American 
women). During the final data analysis, women were dichotomized into two age groups, 
women under 50 and women over 50 years old. This method was used to look at how 
these variables effected women that were either premenopausal versus postmenopausal. 
The study analyzed the reproductive variables of gravidity, parity, number of 
pregnancies, number of full-term pregnancies, age at first full-term pregnancy, and years 
since last full-term pregnancy. Associated breastfeeding variables analyzed were; ever 
breastfed versus never breastfed, ever breastfed for more than 2 weeks versus never 
breastfed, total duration of breastfeeding (in months), and total duration of breastfeeding 





In both European-American and African-American women, a reduction in risk 
was identified with each full-term pregnancy across a woman’s lifetime. In European-
American women, the reduction in risk was 13% among younger women (ages 35-49 
years) and 10% among older women (ages 50-64 years); among African-American 
women there was a 10% reduction in young women and a 6% reduction in older women 
(Ursin et al., 2004). Overall risk also decreased significantly with each additional full-
term pregnancies across both races and age categories. It was also noted that although 
African-American women tended to have more children than European-American 
women, breast feeding rates were much lower in younger African-American women 
versus younger European-American women (see Table 7). The duration of lactation was 
inversely associated with breast carcinoma risk among younger European-American 
(trend p = 0.0001) and African-American (trend p = 0.01) women (Ursin et al., 2004). 
Based on these findings, the researchers note that if young African-American women are 
giving birth to fewer children than in the past, and there is not a significant increase in 
breastfeeding, breast cancer incidence will continue to rise at a rapid rate among this 





Table 7  
Distribution of Parity and Breastfeeding Practices among Control Patients by Age and 
Race Characteristic 
 European-American  African-American 
Characteristic 35-49 yrs 50-64 yrs  35-49 yrs 50-64 yrs 
No. of parous women (% of 
all women) 1130 (74.7) 1307 (87.2)   698 (83.7)  730 (88.8) 
Mean no. of live births among 
parous women +SE 2.2 + 0.03 2.9 + 0.04  2.5 + 0.05 3.4 + 0.08 
No. of women (% of all 
women) with first live birth at 
age <19 yrs  126 (8.3)  170 (11.3)   235 (28.2)  276 (33.6) 
No. of women (% of all 
women) with >3 live births  120 (7.9)  343 (22.9)   132 (15.8)  293 (35.6) 
No. breastfeeding (% of all 
parous women)  848 (75.0)   770 (58.9)   338 (48.4)   376 (51.5) 
Mean no. of months 
breastfeeding (among women 
who breastfed) +SE 15.0 + 0.62 9.0 + 0.47  9.4 + 0.76 10.8 + 0.73 
Note. SE: standard error. Adapted from ―Reproductive Factors and Risk of Breast Carcinoma in a Study of 
White and African-American Women,‖ Ursin, G., Bernstein, L., Wang, Y., Lord, S. J., Deapen, D., Liff, J. 
M., Norman, S. A., Weiss, L. K., Daling, J. R., Marchbanks, P. A., Malone, K. E., Folger, S. G., 
McDonald, J. A., Burkman, R. T., Simon, M. S., Strom, B. L., & Spirtas, R., 2004, Cancer, 101, p.  353-
362. Copyright 2010 by American Cancer Society. Adapted with permission. 
Body Mass Index 
The relationship between obesity and breast cancer risk is a complex issue. 
Studies have found that premenopausal women exhibit an inverse relationship between 
body mass index (BMI) and breast cancer risk (John, Sangaramoorthy, Phipps, Koo, & 
Horn-Ross, 2011; Peacock, White, Daling, Voigt, & Malone, 1999; Swanson et al., 
1996). However, breast cancer risk among postmenopausal women increases as BMI 
increases (Lacey et al., 2009; Morimoto et al., 2002). Obesity has been linked to an 





disease, high-cholesterol, hypertension, and arthritis (Flegal, Carroll, Ogden, & Curtin, 
2010; Malnick & Knobler, 2006). High BMI has also been found to increase mortality 
rates among women with breast cancer across all ages and ethnicities (Dal Maso et al., 
2008; Daling et al., 2001; Ewertz et al., 2011).  
Daling et al. (2001) conducted a study investigating survival in relation to body 
mass index (BMI) among women who were diagnosed with breast cancer before the age 
of 45 (n = 1,177). The researchers found that women who were in the highest quartile of 
BMI (>25.847 kg/m
2
) were 2.5 times more likely to die from breast cancer related illness, 
when compared to women who were in the lowest BMI quartile (<20.639 kg/m
2
; Daling 
et al., 2001). 
Genetic Risks 
As previously discussed genetic mutations such as BRCA1 or BRCA2 can 
considerably increase a woman’s risk for breast cancer. BRCA1 and BRCA2 are tumor 
suppressor genes. In normal cells, BRCA1 and BRCA2 stabilize the cell’s genetic 
material and prevent uncontrolled cell growth (the formation of a tumor). Although the 
actual percentage of breast cancer that is found to be due to BRCA1 and BRCA2 
mutations is relatively low at 5-10% (ACS, 2009a); the gene-disease association itself has 
been found to be strong (Evans, Skrzynia, Susswein, & Harlan, 2006). Although an 
overrepresentation of the mutations among a specific racial or ethnic group has not been 
identified, women from Ashkenazi Jewish ancestry have been noted to have a slightly 
higher risk of carrying the mutations (Petrucelli, Daly, Bars Culver, & Feldman, 2007). 





BRCA2. These mutations within the DNA can be due to things such as exposure to 
natural and medical radiation or environmental contaminants (Campeau, Foulkes, & 
Tischkowitz, 2008; Petrucelli et al., 2007).  
Antoniou et al. (2003) performed a meta-analysis utilizing pooled pedigree data 
from 22 studies involving 8,139 index case patients including 500 patients who carried 
BRCA1 or BRCA2 mutations. The average cumulative risks in BRCA1 carriers by age 
70 years were 65% (95% confidence interval 44%-78%) for breast cancer, the average 
cumulative risk in BRCA2 carriers were 45% (31%-56%) and 11% (2.4%-19%). It was 
also found that the relative risk of breast cancer significantly declined with age for 
BRCA1 carriers, but not with BRCA2 carriers. As previously discussed, women that 
carry BRCA1 and BRCA2 mutations are encouraged to consider preventative measures 
due to their increased risk of breast cancer. These preventative measures are complex and 
involve various levels of risk; therefore it is imperative that women understand their 
actual risk and what each option entails in order to make an informed decision. 
Environmental Risk 
Another factor that may contribute to breast cancer risk is environmental 
exposures. Although it is not specifically known exactly how environmental exposures 
interact with genetic and hormonal factors, research has associations between certain 
endocrine disrupting compounds, organic solvents, and polycyclic aromatic hydrocarbons 
(PAHs) in occupational settings (Hansen, 1999; Labrèche, Goldberg, Valois, & Nadon, 
2010; Peplonska et al., 2010; Zota, Aschengrau, Rudel, & Brody, 2010). Identifying an 





assessment tools, latency, and variations in susceptibility, and differentiation between 
direct and indirect exposures (Laden & Hunter, 1998). 
A prospective, nested case-control study was performed in 2007 (Cohn, Wolff, 
Cirillo, & Sholtz) to investigate whether DDT (dichloro-diphenyl-trichloroethane) 
exposure in young women predicted breast cancer. DDT was a pesticide that was used to 
control insect pests on crop and forest lands, in homes and gardens, and for industrial and 
commercial purposes. It was heavily used from the 1940s until its ban in 1972 
(Environmental Protection Agency, 2010). The researchers utilized blood samples 
obtained from young women between 1959-1967. The women were participating in the 
Child Health and Development Studies, Oakland, California. Blood samples were 
provided 1-3 days after giving birth (mean age, 26 years). Cases (n = 129) had developed 
breast cancer before the age of 50 years, and controls (n = 129) were matched to cases on 
birth year. 
All subjects tested had detectable levels of DDT (≥ 0.8 μg/L), 65% had 
measurements of above the minimum detectable level (0.4 μg/L). The researchers found a 
5-fold increase in the association between breast cancer and DDT among women born 
after 1931; these women were between 14 and 20 years of age when DDT usage peaked. 
Women who were not exposed DDT before 14 years of age (born prior to 1931) showed 
no association between DDT and breast cancer (p = 0.02 for difference by age). It was 
also noted that approximately 78% of cases and 74% of controls reported no residence on 
a farm, which suggests that the majority of DDT exposure occurred in an urban 





household pest control. Although there are noted limitations within the study; such as 
sample size and confounding factors, the researchers feel that this illustrates that 
exposure to DDT in early life may increase breast cancer risk.  
The Cape Cod Breast Cancer and Environment Study investigated whether the 
use of household cleaners and pesticides increases breast cancer risk. This study 
investigated women's exposures to contaminants in tap water, to include endocrine 
disrupting chemicals and chemicals known to cause mammary cancer in animals (Zota et 
al., 2010). Cases (n = 787) were diagnosed with breast cancer between 1988 and 1995, 
and controls (n = 721) were matched to cases on decade of birth and vital status. 
Participants self-reported product use and measured their beliefs about what causes breast 
cancer, or increases a woman’s risk for breast cancer. In order to address potential recall 
bias in self-reporting, the researchers stratified product-use odds ratios by beliefs about 
how contaminants may contribute to breast cancer. These results were then compared 
with odds ratios for family history of breast cancer, stratified by beliefs and conceptions 
about heredity breast cancer.  
The researchers found that breast cancer association increased two-fold in the 
highest quartile of self-reported combined cleaning product use (adjusted OR = 2.1), and 
combined air freshener use (adjusted OR = 1.9) in comparison to the lowest quartile. 
Respective odds ratios for women reporting ever use of air freshener spray (OR = 1.2), 
solid air freshener (OR = 1.7), and mold or mildew control (OR = 1.7) was also 
associated with an increased risk. The researchers also noted positive dose responses 





significant findings associated with pesticide use across all quartiles. The researchers also 
noted that cleaning products odds ratios were elevated among participants who believed 
pollutants contribute a lot to breast cancer and moved towards the null among 
participants who felt pollutants contributed a little or not at all. Among women who 
believed that that heredity contributes a lot to breast cancer, the odds ratio was higher 
(OR = 2.6), than other women within the study (OR = 0.7). Zota et al. (2010), conclude 
that the results of the study suggest that cleaning product use contributes to increased 
breast cancer risk. 
The authors note that their results contradict those from Teitelbaum et al. (2007), 
which was a case-control study investigating the association between self-reported 
residential pesticide use and breast cancer risk among women living in Long Island, New 
York. The study population was comprised of 1,508 women who were diagnosed with 
breast cancer between 1996 and 1997; and 1,556 randomly selected, age-matched 
controls. Participants were interviewed in detail about pesticide use in and around their 
homes, insect repellant use, lice control product use, and the use of flea and tick control 
products on their pets. The researchers calculated overall pesticide use based on the sum 
of the lifetime reported applications across all of the identified categories. Two groups 
consisting of combined products were also analyzed; this included a lawn and garden 
grouping and nuisance pest grouping. Unlike the study by Zota et al.(2010), the authors 
found that among the women who were in the highest quintiles of pesticide use, there was 
a 30% increased risk of breast cancer in comparison to those women who were in the 





however, that the results of both studies further illustrates the complexity of retrospective 
self-report studies when attempting to base valid associations while controlling for the 
potential of recall bias. 
Breast Cancer Risk Reduction 
A woman who has an average risk of breast cancer can reduce her probability of 
getting breast cancer by various lifestyle and behavior modifications. These 
modifications can include quitting smoking (Cui, Miller, & Rohan, 2007), adopting a 
low-fat diet (Prentice et al., 2006), and increasing physical activity (Brody et al., 2007; 
Reeves et al., 2007; Speck, Schmitz, Lee, & McTiernan, 2011). These targeted health 
behavior modifications can decrease the overall risk of breast cancer as well as improve a 
woman’s basic health (Speck et al., 2011).  
In addition to behavior modification, the prevention choices for high risk women 
who have a genetic mutation such as BRCA1 or BRCA2 can include preventative 
mastectomy, chemoprevention, or preventative Oophorectomy (removal of the ovaries). 
These preventative measures are complex and involve various levels of risk; therefore it 
is imperative that women understand their actual risk and what each option entails in 
order to make an informed decision. Another less invasive option may be to participate in 
intensive preventative screenings in lieu of chemoprevention or surgical intervention; 
however, this alternative does not guarantee an improved survival rate when compared to 





Racial and Ethnic Disparities 
Although breast cancer is the most common type of cancer among women 
regardless of race or ethnicity, there are measureable disparities across these groups when 
looking at incidence, prevalence, and survival (ACS, 2009d; Hall et al., 2005; Joslyn et 
al., 2005). Currently, breast cancer is the second leading cause of cancer related deaths 
among European-American and African-American women, and is the first leading cause 
of cancer related deaths among Hispanic women (ACS, 2009e).  
Among Hispanic women, breast cancer is the most common type of cancer 
diagnosed, with an estimated 14,200 new cases being diagnosed, and 2,200 deaths in 
2009 (ACS, 2009e). Young Hispanic women can be at an increased risk of breast cancer 
for many of the same reasons as their older counterparts. Specific risk factors that cannot 
be modified include family history, later age at menarche, late menopause, and genetic 
factors (BRCA1 or BRCA2 mutations; Anders et al., 2008; Baquet et al., 2008; 
Yankaskas, 2006). Whereas factors such as multiparity, postmenopausal obesity, use of 
postmenopausal hormones, alcohol consumption, diet, and lack of physical activity are 
modifiable. The overall incidence rate of breast cancer in Hispanic women is 27% lower 
than that of non Hispanic European-American women (ACS, 2009e). Approximately 7% 
of this difference in incidence may be attributed to the protective effect of reproductive 
patterns among Hispanic women such as lower age at first birth and multiparity (Sweeny 
et al., 2008). Other possibilities include less use of hormone replacement therapy 
following menopause or under utilization of diagnostic services (Shavers et al., 2003; 





Another area that has been found to have racial/ethnic disparities is follow-ups 
after an abnormal mammogram. Press, Carrasquillo, Sciacca, and Giardina (2008) 
investigated possible disparities in follow-up after an abnormal mammogram. The cohort 
was made up of 6,722 women who had an abnormal mammogram, which had been 
performed at an academic medical facility in New York. The cohort included 2,143 
(32%) European-American women, 915 (14%) African-American women, 3,291 (49%) 
Hispanic women, and 373 (6%) women from Asian or other racial/ethnic groups. The 
outcome measure was the number of days between the abnormal mammogram and 
follow-up appointment. The authors (2008) defined five factors that may contribute to 
disparities found in the steps between detection and diagnosis: 
(a) African-American and Hispanic women seek medical help at a later stage of 
breast cancer; (b) minority women experience delays in the initiation and 
completion of treatment; (c) there are differences in the type of treatment received 
by African-American and Hispanic women; (e) African-American women are 
more likely to receive fewer cycles of the expected treatment compared with 
European-American women; and (f) African-American women present with a 
more aggressive form of breast cancer. (Press et al., 2008) 
Both African-American and Hispanic women had a significantly greater time to 
diagnostic follow-up when compared to European-American women. The median time 
for diagnostic follow-up was 21 days for Hispanic women, 20 days for African-American 
women, and 14 days for European-American women. After 30 days, 75% of African-





European-American women. At the 60 day mark, 90% of women across all of the groups 
had received follow-up care, although some women were still less likely to have received 
follow-up imagining in conjunction with an office visit (p < 0.01 for Hispanic vs. 
European-American women).  
As previously noted, many of the same factors that put older women at an 
increased risk of cancer also effect young women. One such factor is African-American 
race (Anders et al., 2008; Baquet et al., 2008; Yankaskas, 2006). Breast cancer is the 
most common type of cancer diagnosed in African-American women; with an estimated 
19,540 new cases being diagnosed, and 6,020 deaths in 2009 (ACS, 2009d). The overall 
incidence of breast cancer in African-American women is 10% lower than European-
Americans; however, when adjusting for age, African-American women under 40 have a 
higher incidence rate (Joslyn et al., 2005; ACS, 2009d). The age-specific incidence rates 
among African-American women under 40 as compared to European-American women 





Table 8  
Age-Specific (Crude) SEER Incidence Rates by Cancer Site, African-American, 






























20-24 2.2179 **  1.4351 0.1538  ** **  1.2064 ** 
25-29 11.329 0.9311  7.7173 0.7171  ** **  6.8086 ** 
30-34 31.8878 2.6573  25.1645 2.4238  15.6355 **  22.678 2.6933 
35-39 65.2024 9.2325  58.8596 10.3118  47.7134 **  54.0119 9.6021 
Note. Rates are per 100,000. Data source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, 
Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural 
Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey). * Includes Hispanic 
race. ** Statistic not displayed due to less than 16 cases. 
Despite the lower overall incidence of breast cancer among African-American 
women, they continue to have a higher mortality rate than European-American women. 
Breast cancer mortality rates for African-American and European-American women were 
approximately the same in the 1980s, but during the period of 2001-2005, the mortality 
rate for African-American was 37% higher than European-American women. This 
difference in mortality accounted for more than one-third of the overall cancer mortality 
disparity between African-American and European-American women (ACS, 2009d). 
Possible factors that contribute to this disparity include race, aggressive tumor 
characteristics, as well as socioeconomic factors such as access to care, treatment 
choices, and health behaviors (Hall et al., 2005; Shavers et al., 2003; Yankaskas, 2006). 
The 5-year survival rate refers to the percentage of patients who live at least 5 





the 5 years following initial diagnosis. The 5-year relative survival rates also take into 
consideration the fact that some patients with cancer die from other unrelated causes. As 
shown in Table 9, 5-year survival rates are considered to be a more accurate and concise 
way to describe the outlook for patients with a particular type and stage of cancer. The 
overall 5-year relative survival for 1999-2006 from 17 SEER geographic areas was 
89.0% for women of all ages. The overall 5-year relative survival by race was 90.2% for 
European-American women; 77.5% for African-American for women of all ages 
(Altekruse et al., 2010). 
Table 9  




Stage at Diagnosis  Ages <50 Ages 50+ Ages <50 Ages 50+ 
Localized 96.6 99.3 91.6 93.7 
Regional 85.2 84.9 72.3 72.0 
Distant 33.5 22.6 14.5 15.4 
Unstaged 77.6 53.1 52.3 45.2 
Note. Based on the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, 
Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, and 
California, excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey). California excluding 
SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2006. The 
remaining 13 SEER Areas contribute cases for the entire period 1999-2006. Based on follow-up of patients 
into 2007. 
Socioeconomic Status and Socioeconomic Position 
Census data are commonly used in public health research; it allows researchers to 
take specific socioeconomic status (SES) variables into consideration when investigating 





occupation, and income may indicate specific health care choices, potential 
environmental exposures, and access to adequate medical services (Baquet & 
Commiskey, 2000; Koh, 2009; Roetzheim et al., 2000; Smith-Bindman et al., 2006; ACS, 
2009d). When investigating breast cancer; race, ethnicity, and SES are difficult concepts 
to define in theory and practice. Each concept encompasses specific health behaviors, 
treatment choices, comorbid conditions, as well as overall health status (Krieger, 
Emmons, & Williams, 2009; O'Malley et al., 2003; Wallington et al., 2009). In 
discussing SES, it is important to also understand the function of socioeconomic position 
(SEP) and its effect on SES. SEP is mainly comprised of measures including education 
attainment, income, and occupation (Galobardes et al., 2007; Sorensen, Sembajwe, 
Harley, & Quintiliani, 2009). SEP plays an integral part in influencing SES and therefore 
also has an influence on lifestyle, housing choices, health behaviors, income, and cancer 
outcomes (Galobardes et al., 2007). For the purpose of this study, I. referred to these 
variables and functions of SEP as the broader category of SES.  
As previously discussed, although European-American women have the highest 
incidence rates of breast carcinoma; African-American women continue to have the 
highest mortality rates (Hall et al., 2005; Newman et al., 2002). African-American 
women also typically present with poorer prognostic characteristics which have been 
found to be a strong indicator for decreased survival (Shavers et al., 2003; Yankaskas, 
2006). SES is also associated with access to care, age at diagnosis, and more aggressive 
tumor characteristics (Krieger et al., 2009; O'Malley et al., 2003; Roetzheim et al., 2000; 






Various differences in clinical characteristics—such as stage distribution, tumor 
size and grade, lymph node status, and hormone receptor status—have also been noted 
within ethnic/racial groups (Baquet et al., 2008; Biffl, Myers, Franciose, Gonzalez, & 
Darnella, 2001; Newman et al., 2002; Shavers et al., 2003; Swanson et al., 2003). In 
2003, Shavers et al. performed a multivariate logistic regression analysis in order to 
examine racial/ethnic variations in diagnosis, treatment, and survival of breast cancer in 
women under 35. After examination of clinical presentation at diagnosis, the researchers 
identified differences in stage distribution across various racial/ethnic groups. They found 
that both Hispanic women (RR, 0.5), and African-American women (RR, 0.8), were less 
likely than European-American women to be diagnosed with in situ breast cancer. Also, 
African-American women (RR, 0.96) and Hispanic women (RR, 0.97), were slightly less 
likely to be diagnosed with Stage I-II disease than European-American women. The 
researchers also found differences in tumor size across racial/ethnic groups. Both 
African-American and Hispanic women were significantly less likely that European-
American women to be diagnosed with a tumor < 1 cm (RR, 0.6; Shavers et al., 2003).  
When investigating differences in standards of care and treatment, variations were 
documented across all racial/ethnic groups. Both African-American (78.7%) and 
Hispanic (77%) women received axillary lymph node examinations less frequently than 
European-American women (81.4%), even though African-American and Hispanic 
women were more likely to have positive lymph nodes than European-American women 





conservation treatment. In comparison to European-American women, both African-
American (RR, 1.8) and Hispanic (RR, 1.7) women were almost twice as likely not to 
receive cancer-directed surgery for invasive breast cancer. Following cancer-directed 
surgery, African-American (RR, 0.8) and Hispanic (RR, 0.8) women were significantly 
less likely to receive adjuvant radiation therapy (Shavers et al., 2003). The researchers 
note that these differences can be due to a variety of factors such as lack of insurance 
status and fear and fatalism surrounding the utilization of breast cancer screening. 
Another analysis performed by Baquet et al. (2008) found when looking at 
women of all ages, that African-American women were significantly more likely than 
European-American women (9.0% vs. 5.3%, p<0.0001) to be diagnosed with breast 
cancer at an advanced stage. Also, 34.2% of African-American women were diagnosed 
with breast cancer at a regional stage at an increased rate in comparison to European-
American women (27.8%). The analysis performed by Baquet et al. (2008) utilized the 
SEER database in order to calculate specific age-adjusted incidence, mortality, relative 
survival rates, tumor grade, histology and receptor status, and treatment patterns for 
invasive breast cancer among African-American and European-American women of all 
ages. The researchers found that in women under the age of 40, both African-American 
women (44.6%, p<0.05) and European-American women (41.6%, p<0.05) were more 
likely to be diagnosed at a regional stage than their older counterparts (40-49 [38.9% of 
African-American women and 35.2% of European-American women, p<0.0001] and 
women aged 50 or older [31.1% of African-American women and 25.4% of European-





Racial/ethnic disparities have also been noted in tumor size upon primary 
diagnosis. In patients under 35 a difference in median tumor size was found; African-
American women were found to be significantly less likely than European-American 
women have a primary tumor measuring < 1 cm (RR, 0.6), 95% CIs [0.4, 0.8] as were 
Hispanic women (RR, 0.6), 95% CIs [0.4, 0.8; Shavers et al., 2003]. The median sizes of 
primary breast cancer tumors were 2.5 cm for European-American women, 2.8 cm for 
African-American women, and 3.0 cm for Hispanic women (Shavers et al., 2003). 
Swanson et al. (2003) analyzed SEER statistics from 1973-1997 and found that younger 
African-American women (under the age of 45) were presenting with tumors sized 2.0 
cm and larger. Miller, Hankey, and Thomas (2002), analyzed breast cancer in 106,000 
women in order to investigate ethnic differences in tumor stage and size.  
Table 10  
Distribution of Tumor Size by Percentage Among a Selected Population of Female Breast 
Cancer Patients Diagnosed Between 1992-1996 
Tumor Size (cm) 
European-
American 
(n = 84,355)  
African-
American 




(n = 1,385)  
American 
Indian 
(n = 136) 
<1.0 19.0  11.2  12.6  15.3  17.2 
1.0-1.9 38.5  30.5  29.8  36.6  32.8 
> 2.0 42.5  58.3  57.7  48.1  50.0 
Unknown 8.9  11.8  8.6  8.5  5.9 
Note. Adapted from ―Impact of sociodemographic factors, hormone receptor status, and tumor grade on 
ethnic differences in tumor stage and size for breast cancer in U.S. women,‖ Miller, B. A., Hankey, B. F., 
& Thomas, T. L., 2002, American Journal of Epidemiology, 155, p. 534-545. Copyright 2002 by Johns 






African-American women under 45 also had a higher rate of lymph node-positive 
tumors smaller than 2.0 cm (34.2% vs. 28.5%) compared to their older counterparts 
(Swanson et al., 2003). Also, 57.2% of African-American women versus 54.4% of 
European-American women were more likely to have lymph node-positive tumors 
(Swanson et al., 2003). Shavers et al. (2003) found that European-American women (RR, 
1.0) were less likely to have positive lymph nodes upon dissection than both African-
American women (RR, 1.2) and Hispanic women (RR, 1.3). Also, European-American 
women (44.5%) had a lower percentage of multiple positive lymph nodes (>4) than 
African-American women (53.1%) and Hispanic women (57%; Shavers et al., 2003). 
Literature Review of Methods 
O’Malley et al. (2003) investigated survival patterns, based on the effect of SES 
and disease stage on racial/ethnic differences in California breast cancer patients. The 
researchers used data from SEER within the Greater San Francisco Bay Area. The 
clinical covariates included were histology, grade, estrogen receptor (ER) status, 
progesterone receptor (PR) status, radiation, and surgical procedures. The surgical 
procedures covariate was then categorized as: breast-conserving (segmental mastectomy, 
lumpectomy, quadrantectomy, tylectomy, wedge resection, excisional biopsy, and partial 
mastectomy), mastectomy, or none. The study population was comprised of 13,634 
females who were newly diagnosed with breast cancer between 1988 and 1992. The 
population was made up of 10,414 European-American women, 940 African-American 





To adequately measure SES, O’Malley et al. (2003) used census block groups to 
create dichotomous variables for 
(a) low education versus not low education (a cut point of 25% of residents older 
than age 25 not receiving a high school diploma were used as low education), (b) 
low income versus not low income (a cut point of 20% of residents living below 
the poverty line was used as low income), and (c) blue collar was used if 66% or 
more of the residents within the block were employed in blue-collar jobs 
(O’Malley et al., 2003). This cut point method has been validated in previous 
breast cancer research within the San Francisco Bay Area; therefore the 
researchers duplicated this method in order to further build on current research 
rather than utilizing Census track data which are comprised of larger geographic 
units of measurements than Census blocks. (United States Census Bureau, 2000)  
O’Malley et al. (2003) found that although each patient and disease characteristics 
varied significantly by race/ethnicity, the characteristics themselves were not only 
associated with one specific racial/ethnic group. European-Americans were found to be 
older upon diagnosis with a mean age of 61.8 years old, when compared to African-
American women (56.7 years), Hispanic women (56.8 years), and API women (55.5 
years). Across all ethnic groups, the majority of women were diagnosed in the early 
stages of the disease, 76% were stages I and IIA, however, the actual stage upon 
diagnosis varied across ethnic groups. Approximately 64% of African-American women, 
70% of Hispanic women, 71% of API women, and 78% of European-American women 





The analyses using the census block SES variables identified that 8% of patients 
lived in poor neighborhoods, 20% lived in low education neighborhoods, and 30% lived 
in blue-collar neighborhoods. When factoring in race, there was a significant association 
with each of the SES variables being utilized. African-American (49.6%), Asian 
American/Pacific Islander (35.8%), and Hispanic (66.3%) patients were more likely to 
live in low-education neighborhoods in comparison to European-Americans (10.4%). The 
percentage of individuals living in low-income neighborhoods was also lower for 
European-Americans (2.7%) in comparison to Asian American/Pacific Islander (14.8%), 
Hispanics (20.3%), and African-Americans (42.7%). The researchers also identified a 
significant association between the SES variables and stage of disease at primary 
diagnosis. The patients residing in low-income neighborhoods (33%) presented with 
Stage IIB or higher than those who lived in higher-income neighborhoods (24%). It was 
also noted that the women living in low education (30%) and blue-collar neighborhoods 
(29%) were the most likely to present with late-stage disease than the other patients 
(23%). 
The main objective of this study was to investigate survival patterns, based on the 
effect of SES and disease stage on racial/ethnic differences. O’Malley et al., (2003) 
notedthat although the unadjusted risk of death within their study was 1.8 times higher 
for African-Americans than European-Americans, the majority of the excess risk 
identified, could be explained by disease stage at diagnosis. When the researchers 
controlled for disease stage at diagnosis, the excess risk was decreased considerably. 





identified a significant (22%) excess risk of death for African-Americans, consistent with 
previous studies on racial differences in breast cancer survival (Joslyn & West, 2000; 
O’Malley et al., 2003; Roetzheim et al., 2000). The researchers do note a limitation of the 
study based on categorization methods within the SEER database. The categorization of 
patients into four basic racial/ethnic groups leaves room for misclassification. This 
miscategorization can lead to a loss of precision, which has been shown to obscure 
pertinent differences regarding cancer incidence and survival across racial/ethnic 
populations (Lin et al., 2002).  
The Public Health Disparities Geocoding Project (Krieger et al., 2002), was 
performed in order to ascertain which census based area-measure was best suited to 
monitor health disparities tied to geocoded public health data. The authors investigated 
various socioeconomic measures at census tract, census block group, and zip code level 
for Rhode Island (1990 population: 1,003,464), and Massachusetts (1990 population: 
6,016,425), the researchers then connected these socioeconomic variables to the state’s 
primary invasive cancer incidence and mortality rates. Krieger et al. (2002) defined two 
main conditions that are required in order to effectively measure SES: (a) important 
aspects of the geographic areas socioeconomic conditions must be adequately and 
accurately summarized and (b) the socioeconomic data being utilized must be relatively 
and legitimately generalizable across geographic regions as well as measures of time. 
Based on these central criteria, the researchers then created an area-based socioeconomic 
measure for six domains of SEP; occupational class, income, poverty, wealth, education, 





composite-variable measures. The six domains and 11 single-variable measures are 
shown in Table 11. 
Following the analyses of all-cause and cause-specific mortality rates, as well as 
all-cause and site-specific cancer rates, the findings indicated that census tract poverty 
measures: 
(a) consistently detected expected socioeconomic gradients in health across a 
wide range of health outcomes, among both the total population and diverse 
racial/ethnic-gender groups, (b) yielded maximal geocoding and linkage to area-
based socioeconomic data (compared to the block group and Zip code data), (c) 
was readily interpretable to and could feasibly be used by state health department 
staff. (Krieger et al., 2009) 
During the course of the project it was also discovered that considerable bias 
could occur due to spatiotemporal mismatches between ZIP codes and census data. These 
mismatches occur when ZIP codes are added or deleted between census years, as well as 





Table 11  
Constructs and Operational Definitions for Area-based Socioeconomic Measures,* 
Massachusetts and Rhode Island, 1988-1992 
Construct Variable 
Occupational Class  
Working Class Percentage of persons employed in predominantly working-class 
occupations, (i.e., nonsupervisory employees). Operationalized as percentage 
of persons employed in the following 8 of 13 census-based occupational 
groups: administrative support; sales; private household service; other 
service (except protective); precision production, craft, and repair; machine 
operators, assemblers, and inspectors; transportation and material moving; 
handlers, equipment cleaners, and laborers. 
Unemployment Percentage of persons aged 16 years or older in the labor force who are 
unemployed (and actively seeking work). 
Income  
Median household income  Median household income in the year prior to the decennial census ($30,056 
for the United States in 1989). 
Low income Percentage of households with an income <50% of the U.S. median 
household income (i.e., <$15,000 in 1989). 
High income  Percentage of households with an income ≥400% of the U.S. median 
household income (i.e., ≥$150,000 in 1989). 
Gini coefficient A measure of income inequality regarding the share of income distribution 
across the population. Calculated using the standard algorithm employed by 
the U.S. Bureau of the Census to extrapolate the lower and upper ends of the 
income distribution. 
Poverty  
Below U.S. poverty line Percentage of persons below the federally defined poverty line, a threshold 
that varies by the size and age composition of the household; on average, it 
equaled $12,647 for a family of four in 1989. 
Wealth  
Expensive homes Percentage of owner-occupied homes worth ≥$300,000 (400% of the median 
value of owned homes in 1989). 
Educational Level  
Low: less than high school Percentage of persons aged ≥25 years with less than a 12th-grade education. 
High: ≥4 years of college Percentage of persons aged ≥25 years with at least 4 years of college. 
Crowding  
Crowded Households Percentage of households containing more than one person per room. 
Note. Adapted from ―Geocoding and Monitoring of U.S. Socioeconomic Inequalities in Mortality and 
Cancer Incidence: Does the Choice of Area-based Measure and Geographic Level Matter?,‖ Krieger, N., 
Chen, J. T., Waterman, P. D., Soobader, M. J., Subramanian, S. V., & Carson, R., 2002, American Journal 
of Epidemiology, 156, p. 471-482. Copyright by 2002 Johns Hopkins Bloomberg School of Public Health. 





Following the Public Health Disparities Geocoding Project, Singh, Miller, 
Hankey, Feuer, and Pickle (2002) developed a similar construct to be specifically utilized 
for cancer surveillance practices within the United States. The researchers developed an 
area socioeconomic index to examine patterns in all-cancer mortality among men 
between 1950 and 1998, based on socioeconomic position. Eleven census variables were 
analyzed and used to develop an area based socioeconomic position index which was 
then used to stratify the U.S. counties into five dichotomous SEP groups. As shown in 
Table 12, the 11 census variables were education distribution (two variables: percentage 
of population with less than 9 years of education and percentage of population with at 
least 12 years of education), median family income, income disparity (measured as a 
logged ratio of the number of households with less than $10,000 income to those with at 
least $50,000), occupational composition (percentage with a white collar occupation), 
unemployment rate, family poverty rate, median home value, median gross rent, 
percentage of households without access to phone, and percentage of households without 
complete plumbing. The estimated factor loadings for the 11 variables, in the order listed 
above, were -0.83, 0.86, 0.90, -0.84, 0.71, -0.57,-0.87, 0.66, 0.80, -0.80, and -0.65. 
The researchers note that the utilized scale was a standard normal scale, had a 
mean of 0 and a standard deviation of 1. In order to transform the scale into a 
standardized index, the mean was set to 100, and the standard deviation was set to 20 
(Singh, Miller, & Hankey, 2002). Following this adjustment, the index scores ranged 
from a low of -7.74 to a high of 172.65 (Singh, Miller, & Hankey, 2002). When 





status/position and low levels of deprivation. Respectively, a low index score indicates 
low levels of socioeconomic status/position and high levels of deprivation (Singh, Miller, 
& Hankey, 2002). The socioeconomic index created was found to have a high degree of 
reliability, with a reliability coefficient Cronbach’s alpha (α) of 0.94 (Singh, Miller, 
Hankey et al., 2002). 
Table 12  
Census Variables That Make Up the Area Socioeconomic Position Index 
Construct  Census Variable 
Education Distribution  Percentage of population >25 years with less than 9 years of education 
 Percent of population >25 years with at least a High School diploma 
   
Income Distribution  Median family income 
 Income disparity (measured as a logged ratio of the number of households with 
less than $10,000 income to those with at least $50,000) 
 Percent of families below poverty level 
   
Occupational composition  Unemployment rate (% civilian labor force aged >16 years unemployed) 
 Employed persons aged >16 years in white collar occupations 
   
Housing composition  Median home value 
 Median gross rent 
 Percent of occupied housing units without telephone 
 Percent of occupied housing units without complete plumbing 
Note. Adapted from ―Changing area socioeconomic patterns in U.S. cancer mortality, 1950-1998: Part I-All 
cancers among men,‖ Singh, G. K., Miller, B. A., Hankey, B. F., Feuer, E. J., & Pickle, L. W., 2002, 
Journal of the National Cancer Institute, 94,  904-915. Copyright 2002 by Oxford University Press. 






The researchers also performed principal components analysis on the 11 variables 
for different subsets of the U.S. population (across counties with populations of <50,000, 
<100,000, <150,000, <250,000, <500,000, and <1,000,000; which represents 17%, 27%, 
35%, 43%, 58%, and 76% of the total U.S. population; Singh, Miller, Hankey et al., 
2002). The aforementioned factor loadings for all variables remained fundamentally 
unchanged, which indicated a high degree of reliability. 
Summary 
In chapter 2, I reviewed the current literature and statistics that encompass the 
epidemiology of breast cancer in women under 40 years of age. Next, chapter 3 includes 
comprehensive information regarding the study design and methods that were employed 






Chapter 3: Research Method 
This chapter will discuss the study’s research method. It includes a general 
discussion of the target population and sampling timeframes, as well as data collection 
and analysis methods. This chapter will also discuss the eligibility criteria for inclusion in 
the study. The issues of confidentiality and human subjects concerns will also be included 
in this chapter.  
Research Design and Approach 
The primary purpose of this study was to identify an association between 
socioeconomic position (SEP), tumor size, cancer stage, and survival among women 
under 40 with a primary diagnosis of breast cancer. As breast cancer is a clinical and rare 
disease, recruitment of participants would be extremely difficult and beyond my skills, 
especially when the federal government has established a cancer registry for these 
purposes. Therefore, a quantitative, retrospective, cohort study design was utilized in 
order to analyze the incidence and prognostic variations of breast cancer among women 
under 40 years of age. This study was performed by utilizing the SEER Program 
database. The SEER database encompasses 17 population based cancer registries across 
the United States, and it is a program of the NCI. SEER currently collects and analyzes 
cancer incidence and survival data which consists of approximately 26% of the total U.S. 
population to include 23% of African-Americans, 23% of European-Americans, 40% of 
Hispanics, 42% of American Indians and Alaska Natives, 53% of Asians, and 70% of 





A retrospective cohort design involves the use of secondary data in order to 
investigate a specific health outcome or issue that has already occurred in the past within 
a defined population. The baseline measurements and follow-up have already been 
performed, and a dataset for the population has been created. The main advantages of a 
retrospective cohort design include the low-cost, ease of use, and expeditious manner of 
accessing a secondary data set (Young, Mazyck, & Schulz, 2006). Another major 
advantage, as with SEER, is that the dataset is linked to the census data in order to allow 
researchers to investigate disease patterns or trends across different demographic and 
socioeconomic variables. This current design allowed for an analysis of variables such as 
age, socioeconomic position, and survival, based upon specific tumor characteristics such 
as summary stage and size. A disadvantage of a retrospective cohort design is the reliance 
on secondary data that was collected prior to the study. If there were not data 
standardization procedures for the database, there may be incomplete or erroneous 
entries. 
Setting and Sample 
The target population for this study was women aged 20 to 39 with no prior 
history of any type of cancer who were diagnosed with breast cancer between the years of 
2001-2006. The start date of January 1, 2001, was chosen to reflect guidelines put in 
place by the National Comprehensive Care Network, which standardized cancer registry 
reporting SEER (SEER, 2000). By utilizing the data following the standardization 
changes in 2000, it decreased the probability of inclusion due to miscoding within the 






The eligibility criterions for inclusion are; being female, between the ages of 20 
and 39 with a primary diagnosis of breast cancer between the years of 2001 and 2006. 
The SEER database assigns a four-digit CPT code to each type of cancer; this study 
utilized the following codes: C50.0-C50.9. The selection also included a variable for first 
primary malignancy. This variable is based on each patient within the SEER registry. 
Each malignancy is coded in a sequence based on when it was reported. A special marker 
has been built into the SEER Stat program to choose individuals based on the case being 
a first primary malignancy. 
SEER also has data quality management procedures in place to prevent duplicate 
cases for each individual. If there is a conflict within the database—meaning a potential 
duplicate case—a flow chart is followed in order to ascertain if the case truly is a 
duplicate or a secondary diagnosis. The protocol is required by NAACCR in order for 
cancer registries to be certified (NAACCR, 2010). To deconflict potential duplicates, 
registries match cases on individual identifying information in the following order: last 
and first name, social security number, date of birth, SEER cancer site, middle name, age 
at diagnosis, sex, race, date of diagnosis, tumor sequence number, primary site code, 
morphology code, laterality, stage of disease, and class of case (NAACCR, 2010). 
Sampling Method and Procedure 
For the purpose of this study, the independent variable was socioeconomic 
position (SEP). Dependent variables included SEER summary stage, tumor size, and 





stage, and survival by socioeconomic position (SEP) in women under 40 diagnosed with 
breast cancer. Additionally, race was dichotomized and controlled for as a covariate in 
the final analysis.  
Power Analysis 
Statistical power was conducted a priori using G*Power (Faul, Erdfelder, Lang, & 
Buchner, 2007). By definition, the power of a statistical test is the probability to detect an 
effect, or the likelihood that there is no effect, and the null hypothesis will be rejected 
(Faul et al., 2007a). For this study, the likelihood of (a) the rejection of the null 
hypothesis that there is no association between socioeconomic position and tumor size at 
diagnosis, (b) the rejection of the null hypothesis that there is no association between 
socioeconomic position and stage at diagnosis, or (c) the rejection of the null hypothesis 
that there is no association between socioeconomic position and survival; was determined 
by using hierarchical regression. Sample size calculation for logistic regression is a 
complex problem, but Peduzzi, John, Elizabeth, Theodore, & Alvan (1996) suggested the 
following guideline for a minimum number of cases to include in a study. Let p equal the 
smallest of the proportions of negative or positive cases in the population and k equal the 
number of covariates (stage, tumor size, survival, and SEP). The proportion of women 
diagnosed with breast cancer under 40 years of age to the total number of women 
diagnosed with breast cancer was based on Table 1. Therefore the minimum number of 
cases to include is: 





Instrumentation and Materials 
For the purpose of the study, the SEER 17 registry was utilized. The study was 
based on one main assumption that participating cancer registries followed the National 
Comprehensive Care Network cancer registry guidelines, which standardized registry 
reporting as of 2000 (SEER, 2000). The SEER dataset has several limitations. Currently 
the SEER registry dataset is limited to 26% of the United States population. This 
coverage includes 23% of African-Americans, 23% of European-Americans, 40% of 
Hispanics, 42 % of American Indians and Alaska Natives, 53% of Asians, and 70 % of 
Hawaiian/Pacific Islanders (SEER, 2000). The SEER program has a special focus on 
minority racial and ethnic groups as well as urban populations, which, in turn, equates to 
an overrepresentation of minorities within the data set. The overrepresentation of racial 
and ethnic groups within SEER is done in order to ensure sufficient population sizes for 
the purpose of statistical analysis.  
All of the necessary raw data were extracted from the SEER registry DVD 












Table 13  




Socioeconomic Position Measure 
For the purpose of this study, I will refer to these variables and functions of SES 
as the broader category of SEP. Based on the created index and findings of Singh, Miller, 
& Hankey (2002), I utilized the socioeconomic index in Table 14 to measure SEP. Each 
individual patient within the SEER registry has their county of residence (at the time of 
diagnosis) included with their record, this county code became the foundation on which 
SEP was based. The SEER 17 registry is comprised of 17 geographic regions (Figure 2), 
these regions were divided into their respective counties, which were stratified into 
quartiles, analyzed based on the aforementioned socioeconomic position index, and then 
placed into 1 of 5 socioeconomic position categories. 
Item Name SEER variable name Variable Range Type 
Race/Ethnicity Race recode 1 = European-American/Non Hispanic 
0 = African-American 
0 = Hispanic White 
0 = Asian 
0 = Pacific Islander 






in patients lifetime 
First malignant primary 
indicator 
0 = No 
1 = Yes 
Ordinal 
Tumor size EOD-size (1998-2003) 
CS Tumor Size (2003+) 
000, 001-988, 989-995, 999, and 888 Ordinal 
Summary Stage SEER Summary stage 1 = Localized 
2 = Regional 
3 = Distant 
Ordinal 
Survival Survival Time recode MMMM = Survival time in months Continuous 
SEP County Codes were pulled from SEER and used to calculate SEP based on the 11 variables 





When interpreting this scale, a high index score indicates high levels of SEP and 
low levels of deprivation. Respectively, a low index score indicates low levels of SEP 
and high levels of deprivation. Therefore, counties placed in category SEP I are 
considered to have low SEP and a category of SEP V are considered to have a high SEP. 
All of the data that were utilized for the SEP index was derived from the 2000 decennial 
census. 
Table 14  
Census Variables and Data Source for the Area Socioeconomic Position Index 
Construct Census Variable Data Source 
Education 
Distribution 
Percentage of population >25 years with less than 9 years of education Census 2000 dataset 
Percent of population >25 years with at least a High School diploma Census 2000 dataset 
   
Income 
Distribution 
Median family income Census 2000 dataset 
Income disparity (measured as a logged ratio of the number of households 
with less than $10,000 income to those with at least $50,000) 
Census 2000 dataset 
Percent of families below poverty level Census 2000 dataset 
   
Occupational 
composition 
Unemployment rate (% civilian labor force aged >16 years unemployed) Census 2000 dataset 
Employed persons aged >16 years in white collar occupations Census 2000 dataset 
   
Housing 
composition 
Median home value Census 2000 dataset 
Median gross rent Census 2000 dataset 
Percent of occupied housing units without telephone Census 2000 dataset 
Percent of occupied housing units without complete plumbing Census 2000 dataset 
Note. Adapted from ―Changing area socioeconomic patterns in U.S. cancer mortality, 1950-1998: Part I- 
All cancers among men,‖ Singh, G. K., Miller, B. A., Hankey, B. F., Feuer, E. J., & Pickle, L. W., 2002, 
Journal of the National Cancer Institute, 94,  904-915. Copyright 2002 by Oxford University Press. 






Data Collection and Analysis 
The SEER database is the leading source of cancer incidence and survival data 
within the United States. This comprehensive dataset allowed for a large sample size and 
increased power. By utilizing SEER as a secondary data source, I was able to conduct a 
retrospective cohort study in order to examine the possible relationship between SEP, 
tumor size, cancer stage, and survival within this population. The independent variable 
was SEP; the dependent variables were SEER Summary Stage, tumor size, and survival. 
Additionally, race was dichotomized and controlled for as a covariate in the final 
analysis. The statistical model (Table 15) utilized measured the effect of covariates 
individually as well as in the presence of other covariates.  
Table 15  
Statistical Model 
 Predictor Variable 
 SEP Tumor Size Stage Race 
DV = Tumor Size     
Partial Model   X X 
Full Model X  X X 
DV = Stage     
Partial Model  X  X 
Full Model X X  X 
DV = Survival     
Partial Model  X X X 






Research Questions and Hypotheses 
This was a quantitative, retrospective, cohort study of newly diagnosed female 
breast cancer patients under the age of 40. Participants were drawn from the SEER 
Program database (SEER, 2009). More details abou the SEER data are found in chapter 
3. To analyze differences in tumor size, cancer stage, and survival by SEP in women 
under 40 years of age diagnosed with breast cancer, the following research questions and 
hypotheses were utilized for this study.  
1. What is the independent effect of socioeconomic position on tumor size at the 
time of breast cancer diagnosis in women under 40? 
H0:. There is no association between socioeconomic position and tumor size at 
diagnosis. 
H1: There is an association between socioeconomic position and tumor size at 
diagnosis. 
2. What is the independent effect of socioeconomic position on the stage of 
cancer at the time of breast cancer diagnosis in women under 40? 
H0: There is no association between socioeconomic position and the stage of 
cancer at the time of breast cancer diagnosis in women under 40. 
H1: There is an association between socioeconomic position and the stage of 
cancer at the time of breast cancer diagnosis in women under 40. 
3. What is the independent effect of socioeconomic position on survival in 
women under 40 diagnosed with breast cancer?  





H1: There is an association between socioeconomic position and survival. 
Protection of Human Participants 
All data utilized within the context of this study were obtained from the SEER 
cancer registry public web site. This registry is anonymous other than indicators of race 
and age. These variables do not allow registry data to be linked to specific individuals. 
The NCI maintains the SEER database, which is publically available (SEER, 2009). The 
NCI also publishes periodic cancer surveillance reports as well as an Annual Report to 
the Nation on the Status of Cancer (NCI, 2009c). Therefore, this study was based on the 
examination of public records which are completely anonymous. Thus the risk of 
potential harm to human subjects is extremely minimal if at all probable.  
The SEER registry program granted a Limited Use Agreement in writing for use 
in this study (Appendix A). In accordance with Walden University Institutional Review 
Board (IRB) procedures, an application for approval was submitted; data collection and 
analysis commenced upon the final approval from the IRB committee (approval #06-24-
11-0019763).  
Dissemination of Findings 
In order to uphold Walden University’s ongoing commitment to social change, 
the study results will be disseminated via publications from the dissertation to the 
appropriate peer-reviewed journals in the field. Submissions for poster presentations and 






Chapter 4: Results 
The purpose of this quantitative, retrospective, cohort study was to evaluate 
differences in tumor size, tumor stage, and survival by socioeconomic position in women 
under 40 years of age diagnosed with breast cancer. This chapter begins with the 
descriptive statistics for the study population, sociodemographic variables, and clinical 
characteristics for each variable of interest. The chapter will then discuss the results of 
the analyses for the three research questions:  
1. What is the independent effect of socioeconomic position on tumor size at the 
time of breast cancer diagnosis in women under 40?  
2. What is the independent effect of socioeconomic position on the stage of 
cancer at the time of breast cancer diagnosis in women under 40?  
3. What is the independent effect of socioeconomic position on survival in 
women under 40 diagnosed with breast cancer?  
The data were obtained from the SEER Program database, SEER 17 Registry for 
all primary breast cancers reported between the years 2001-2006. The SEER database 
encompasses 17 population based cancer registries across the United States, and it is a 
program of the NCI. SEER currently collects and analyzes cancer incidence and survival 
data which consists of approximately 26% of the total U.S. population to include 23% of 
African-Americans, 23% of European-Americans, 40% of Hispanics, 42% of American 
Indians and Alaska Natives, 53% of Asians, and 70% of Hawaiian/Pacific Islanders 





In order to obtain the data from SEER 17 for analysis, a case listing was created 
using the selection tab to define the parameters for the study population. This case listing 
included females ages 20 to 39 who had a primary diagnosis of breast cancer (CPT codes 
C50.0-C50.9) in the years 2001-2006, had a first primary malignancy indicator, and 
whose records included coding for both stage and tumor size upon diagnosis. There were 
819 women who were excluded due to invalid or missing entries for tumor size, and 61 
women were excluded due to missing or invalid summary stage. Women whose survival 
was coded as 0 were also excluded due to the fact that diagnosis occurred at the time of 
autopsy or listing on the death certificate; this exclusion criteria accounted for 41 total 
cases. Additionally, 28 cases were excluded from the state of Alaska. These cases were 
part of the Alaska Natives Registry and did not include county level geocoding; therefore, 
county level SEP could not be calculated. These delineations resulted in 14,696 eligible 




 Statistics 18 (IBM, 
2009) for the complete analysis. 
 
As previously noted, SEER does not collect data on health habits such as 
smoking, sedentary lifestyle, breast feeding behaviors, or obesity; therefore these 
confounding factors were not controlled for during the data analysis, a limitation of this 
study. SEER does, however, collect socioeconomic measures at a county level. In 
constructing the 11 variable measure of SEP, I obtained all socioeconomic position data 
from the 2000 decennial census to ensure the integrity and cohesiveness of the final SEP 
measure. For the purpose of this study, SEP was comprised of 11 census variables: 





education and percentage of population with at least 12 years of education), median 
family income, income disparity (measured as a logged ratio of the number of households 
with less than $10,000 income to those with at least $50,000), occupational composition 
(percentage with a white collar occupation), unemployment rate, family poverty rate, 
median home value, median gross rent, percentage of households without access to 
phone, and percentage of households without complete plumbing. All of the 
aforementioned variables were extracted from the 2000 decennial census utilizing 
DataFerrett. DataFerrett stands for Federated Electronic Research, Review, Extraction, 
and Tabulation Tool (United States Census Bureau, 2010). DataFerrett is a web based 
data extraction and analysis tool provided by the U.S. Census Bureau. This tool is open 
access and readily available at no cost for public use. 
All counties included in the 2000 decennial census were analyzed based on the 
aforementioned socioeconomic index and then stratified into one of five socioeconomic 
position categories. When interpreting this scale, a high index score indicates high levels 
of SEP and low levels of deprivation. Respectively, a low index score indicates low 
levels of SEP and high levels of deprivation. Therefore, counties were placed in the 
following categories: (a) SEP I, low socioeconomic position and high deprivation; (b) 
SEP II, moderately low socioeconomic position and moderately high deprivation; (c) SEP 
III, medium socioeconomic position and medium deprivation; (d) SEP IV, moderately 
high socioeconomic position and moderately low deprivation; and (e) SEP V, high 








Table 16  
Sociodemographic and Clinical Characteristics of Study Population 
 SEP I SEP II SEP III SEP IV SEP V Total n (%) 
ETHNICITY 
b
       
European-American  389 (55.6%)  367 (57.8%)  622 (52.2%)  1555 (47.2%)  5683 (64.0%)  8616 (58.6%) 
African-American  152 (21.7%)  115 (18.1%)  305 (25.6%)  472 (14.3%)  972 (11.0%) 2016  (13.7%) 
American Indian/Alaska Native  16 (2.3%)  4 (.63%)  4 (.34%)  14 (.43%)  39 (.44%)  77 (.52%) 
Asian or Pacific Islander  13 (1.9%)  26 (4.1%)  47 (3.9%)  349 (10.6%)  1064 (12.0%)  1499 (10.2%) 
Spanish-Hispanic-Latino  130 (18.6%)  123 (19.4%)  214 (18.0%)  903 (27.4%)  118 (12.6%)  2488 (16.9%) 
TUMOR SIZE 
b
       
< 2 cm  237 (33.9%)  212 (33.4%)  393 (33.0%)  1238 (37.6%)  3721 (41.9%)  5801 (39.5%) 
2-5 cm  365 (52.14%)  342 (53.9%)  597 (50.1%)  1591 (48.3%)  4102 (46.2%)  6997 (47.6%) 
> 5 cm  98 (14.0%)  81 (12.8%)  202 (16.9%)  464 (14.1%)  1053 (11.9%)  1898 (12.9%) 
SUMMARY STAGE       
Localized  341 (48.7%)  312 (49.1%)  553 (46.4%)  1657 (50.3%)  4322 (48.7%)  7185 (48.9%) 
Regional  327 (46.7%)  287 (45.2%)  573 (48.1%)  1500 (45.6%)  4154 (46.8%)  6841 (46.6%) 
Distant  32 (4.6%)  36 (5.7%)  66 (5.5%)  136 (4.1%)  400 (4.5%)  670 (4.6%) 
SURVIVAL 
a
       
1-12 Months  33 (4.7%)  33 (5.2%)  85 (7.1%)  171 (5.2%)  393 (4.4%)  715 (4.9%) 
13-24 Months  150 (21.4%)  106 (16.7%)  237 (19.9%)  691 (21.0%)  1721 (19.4%)  2905 (19.8%) 








 SEP I SEP II SEP III SEP IV SEP V Total n (%) 
37-48 Months  118 (16.9%)  102 (16.1%)  202 (16.9%)  571 (17.3%)  1521 (17.1%)  2514 (17.1%) 
49-60 Months  101 (14.4%)  105 (16.5%)  162 (13.6%)  477 (14.5%)  1340 (15.1%)  2185 (14.9%) 
61-72 Months  98 (13.1%)  83 (13.1%)  141 (11.8%)  450 (13.7%)  1213 (13.7%)  1979 (13.5%) 
73-83 Months  80 (11.4%)  82 (12.9%)  138 (11.6%)  375 (11.4%)  116 (12.6%)  1791 (12.2%) 










Table 16 presents the descriptive sociodemographic and clinical characteristics of 
newly diagnosed breast cancer cases from 2001 to 2006. The study population was 
comprised of 14,696 women ages 20-39 with the largest percentage of women were ages 
35-39 (64.1%). The majority of the women were European-American (58.6%) followed 
by Hispanic (16.9%), African-American (13.7%), and Asian (10.2%). The majority of 
women (60.4%) were classified as high socioeconomic position and low deprivation, 
while 22.4% were classified as moderately high position and moderately low deprivation. 
Survival time ranged from 1 to 83 months, with the three most prevalent survival times 
being 13-24 months (19.8%), 25-36 months (17.7%), and 37-48 months (17.1%). The 
majority of women had tumor summary staged as either localized (48.9%) or regional 
(46.9%) and tumor sizes of less than 2 cm (39.5%), 2-5 cm (47.6%), or greater than 5 cm 
(12.9%). Bivariate analyses examining the association between SEP, ethnicity, and tumor 
characteristics indicated that SEP was significantly associated with ethnicity (p<.000), 
tumor size (p<.000), overall survival (p<.035) and summary stage (p<.0248). 
Data Collection and Analysis 
The SEER database is the leading source of cancer incidence and survival data 
within the United States. This comprehensive dataset allowed for a large sample size and 
increased power. By utilizing SEER as a secondary data source, I was able to conduct a 
retrospective cohort study in order to examine the possible relationship between SEP, 
tumor size, cancer stage, and survival within this population. The independent variable 





Additionally, race was dichotomized and controlled for as a covariate in the final 
analysis. 
Research Question 1 
The first research question this study was as follows: What is the independent 
effect of socioeconomic position on tumor size at the time of breast cancer diagnosis in 
women under 40? H0: There is no association between socioeconomic position and tumor 
size at diagnosis. H1: There is an association between socioeconomic position and tumor 
size at diagnosis. 
Hierarchical regression analysis was conducted to assess the ability of SEP to 
predict tumor size after controlling for ethnicity and cancer summary stage. Ethnicity and 
cancer summary stage were entered in the partial model in Step 1, explaining 13% of the 
variance in tumor size. After entry of SEP in the full model in Step 2, the total variance 
explained by the model was 13.2%, F(3, 14,692) = 745.71, p < .01. SEP explained .2%, F 
change (1, 14,692) = 42.28, p< .01 (see Table 17). In the final model, all three variables 
made a significant contribution to the model, with cancer summary stage reporting the 
highest beta value (β = .389, p< .01), indicating that as cancer summary stage scores 
increased tumor size also increased. Ethnicity had the next highest beta value (β = .106, p 
< .01) indicating that non Caucasians have higher tumor sizes than Caucasians. Finally, 
the beta values of SEP (β = -.050, p < .01) indicated that as SEP increased, tumor size 
decreased. Based on these results, the null hypothesis that SEP is not a significant 





Table 17  
Hierarchical Regression: SEP and Tumor Size, Controlling for Ethnicity and Summary 
Stage 





Step 1:    .130**  
Ethnicity .151 .011 .110**   
Summary Stage .389 .009 .336**   
Step 2:    .132** .002** 
Ethnicity .146 .011 .106**   
Summary Stage .389 .009 .336**   
SEP -.031 .005 -.050**   
Note. ** = p < .01; N = 14,696 
The parameter estimates shown in Table 18 indicate that for women with a tumor 
size less than 2 cm, cancer summary stage, SEP, and ethnicity make a significant 
contribution to the model (p<.05). As cancer summary stage increases by 1 unit, the 
women were .14 times less likely to have a tumor size of less than 2 cm versus a tumor 
size of greater than 5 cm. As the SEP increases by 1 unit, the likelihood of having a 
tumor size of less than 2 cm versus greater than 5 cm increases by a factor of 1.14. 
For the 2 cm to 5 cm model, cancer summary stage and race made a significant 
contribution to the model but SEP did not. A 1-unit increase in cancer summary stage 
decreased the likelihood of a 2 cm tumor versus a tumor greater than 5 cm by .34 times.  
The results of the coefficients table (Table 19) indicate that race, cancer summary stage, 
and SEP all make a significant contribution to the model (p<.05). Specifically, the beta 
coefficients indicate that SEP is associated with decreases in tumor size. Conversely, 





Additionally, non European-Americans have significantly larger tumor sizes than 
European-Americans. Based on the aforementioned results, the null hypothesis that 
socioeconomic position is not a significant predictor of tumor size was rejected.  
 
Table 18  





Error Wald df Sig. Exp(B) 








Intercept 4.054 .148 755.327 1 .000    
Cancer Stage  -1.951 .052 1417.318 1 .000 .142 .128 .157 
Race 
Dichotomized -.695 .057 147.493 1 .000 .499 .446 .558 
SEP Index .135 .025 27.963 1 .000 1.144 1.088 1.203 
2-5 
cm 
Intercept 3.241 .138 551.038 1 .000    
Cancer Stage -1.067 .047 515.489 1 .000 .344 .314 .377 
Race 
Dichotomized -.283 .053 28.184 1 .000 .753 .678 .836 
SEP Index .026 .023 1.288 1 .256 1.027 .981 1.075 
a





















order Partial Part 
1 (Constant) 1.066 .015  69.970 .000    
Cancer stage .389 .009 .336 43.616 .000 .343 .339 .336 
Race 
Dichotomized .151 .011 .110 14.330 .000 .130 .117 .110 
2 (Constant) 1.200 .026  46.739 .000    
Cancer stage .389 .009 .336 43.677 .000 .343 .339 .336 
Race 
Dichotomized .146 .011 .106 13.788 .000 .130 .113 .106 
SEP Index -.031 .005 -.050 -6.502 .000 -.060 -.054 -.050 
a
. Dependent Variable: Tumor Size 
Research Question 2 
The second research question for this study aimed was as follows: What is the 
independent effect of socioeconomic position on the stage of cancer at the time of breast 
cancer diagnosis in women under 40? H0: There is no association between socioeconomic 
position and the stage of cancer at the time of breast cancer diagnosis in women under 40. 
H1: There is an association between socioeconomic position and the stage of cancer at the 
time of breast cancer diagnosis in women under 40. 
Hierarchical regression analysis sought to determine if SEP predicted cancer 
summary stage after controlling for tumor size and ethnicity. Tumor size and ethnicity 
were entered in the partial model at Step 1 and explained 11.8% of the variability in 





explained for the full model remained at 11.8%, F(3, 14,695) = 655.08, p < .01 (Table 
20). All three variables made a significant contribution to the final model. Specifically, as 
tumor size increased (β = .342, p < .01) so too did summary stage. Increases in SEP index 
scores which indicate high levels of SEP and low levels of deprivation; (β = .017, p = 
.03) were also associated with increases in summary stage. The beta values for ethnicity 
(β = .016, p = .046), revealed that non European-Americans had higher summary stages 
than European-Americans. Given the significant contribution of SEP to the final model, 
the null hypothesis that SEP is not a significant predictor of cancer stage was rejected.  
The results of the coefficients table (see Table 21) indicate that race, tumor size, 
and SEP make a significant contribution to the model (p<.05). Specifically, the beta 
coefficients indicate that as tumor size, and SEP increase, there are also increases in 
cancer summary stage classifications. Additionally, non European-Americans have a 
significant higher summary stage classification than European-Americans. 
Table 20  
Hierarchical Regression: SEP and Summary Stage, Controlling for Ethnicity and Tumor 
Size 





Step 1:    .118**  
Ethnicity .017 .009 .014   
Tumor Size .294 .007 .341**   
Step 2:    .118**  
Ethnicity .018 .009 .016*   
Tumor Size .295 .007 .342**   
SEP .009 .004 .017*   






Table 21  














order Partial Part 
1 (Constant) 1.039 .013  82.098 .000    
Tumor Size .294 .007 .341 43.616 .000 .343 .339 .338 
Race 
Dichotomized .017 .009 .014 1.841 .066 .059 .015 .014 
2 (Constant) .998 .022  44.371 .000    
Tumor Size .295 .007 .342 43.677 .000 .343 .339 .338 
Race 
Dichotomized .018 .009 .016 1.996 .046 .059 .016 .015 
SEP Index .009 .004 .017 2.204 .028 -.005 .018 .017 
a
 Dependent Variable: Cancer summary stage 
Research Question 3 
The final research question this study aimed to address was as follows: What is 
the independent effect of socioeconomic position on survival in women under 40 
diagnosed with breast cancer? H0: There is no association between socioeconomic 
position and survival. H1: There is an association between socioeconomic position and 
survival. 
Hierarchical regression analysis was conducted to assess the ability of SEP to 
predict survival time after controlling for ethnicity, summary stage, and tumor size. 
Ethnicity, summary stage, and tumor size were entered into the partial model at Step 1. 





added to the full model in Step 2, there was no change in the explained variance for the 
full model, F(4, 14,691) = 126.23, p < .01 (Table 22). Results also indicated that 
summary stage (β = -.107, p < .01), tumor size (β = -.082, p < .01), and ethnicity (β = -
.078, p < .01) all made significant contributions to the model, while SEP (β = .010, p = 
.24) did not. Based on the results of this analysis, the null hypothesis that SEP is not a 
significant predictor of survival time after controlling for summary stage, tumor size, and 
ethnicity; was accepted.  
The results of the coefficients table (Table 23) indicate the ethnicity, tumor size, 
and cancer summary stage make a significant contribution to the model (p<.05). 
However, SEP does not make a significant contribution to the model. Specifically, the 
beta coefficients indicate that increases in tumor size, and cancer summary stage are 
associated with lower survival times, and that non European-Americans have a 





Table 22  
Hierarchical Regression: SEP and Survival Time, Controlling for Ethnicity and Tumor 
Size and Summary Stage 





Step 1:    .033**  
Ethnicity -3.418 .356 -.079***   
Tumor Size -2.612 .276 -.082**   
Summary Stage -3.945 .318 -.107**   
Step 2:    .033  
Ethnicity -3.388 .357 -.078**   
Tumor Size -2.595 .277 -.082**   
Summary Stage -3.952 .318 -.107**   
SEP .189 .159 .010   




















order Partial Part 
1 (Constant) 55.374 .589  93.986 .000    
Tumor Size -2.612 .276 -.082 -9.451 .000 -.129 -.078 -.077 
Summary stage -3.945 .318 -.107 -12.408 .000 -.140 -.102 -.101 
Race 
Dichotomized -3.418 .356 -.079 -9.613 .000 -.096 -.079 -.078 
2 (Constant) 54.531 .923  59.058 .000    
Tumor Size -2.595 .277 -.082 -9.374 .000 -.129 -.077 -.076 
Summary stage -3.952 .318 -.107 -12.427 .000 -.140 -.102 -.101 
Race 
Dichotomized -3.388 .357 -.078 -9.501 .000 -.096 -.078 -.077 
SEP Index .189 .159 .010 1.186 .236 .021 .010 .010 
a
 Dependent Variable: Survival Time 
Summary 
The purpose of this quantitative, retrospective, cohort study was to evaluate 
differences in tumor size, tumor stage, and survival by socioeconomic position in women 
under 40 years of age, diagnosed with breast cancer. This chapter presented descriptive 
statistics of the sample and hypotheses testing findings for the three research questions 
posed. The study aimed to answer whether there was an independent effect of 
socioeconomic position on tumor size and stage of cancer at the time of breast cancer 
diagnosis in women under 40, and survival time after diagnosis with breast cancer also in 





The findings of the first question indicate that there were significant differences 
across SEP categories and tumor size. Therefore, the null hypothesis stating that there is 
no association between socioeconomic position and tumor size at diagnosis was rejected. 
The findings of the second question indicate race, tumor size, and SEP all had a 
significant impact on cancer stage at diagnosis. Therefore, the null hypothesis stating that 
there is no association between SEP and the stage of cancer at the time of breast cancer 
diagnosis in women under 40 was rejected. The findings of the third question indicated 
that while ethnicity, tumor size, and cancer summary stage had a significant effect on 
survival time, SEP did not. Therefore the null hypothesis stating that there is no 
association between SEP and survival time in women under 40 was not rejected. 
Chapter 4 presented the study demographics and results in order to answer the 
overarching research question: Are there differences in tumor size, cancer stage, and 
survival based on socioeconomic status in women less than 40 year of age? Chapter 5 
discusses the results in depth, implications for positive social change, and offers 





Chapter 5: Discussion, Conclusions, and Recommendations 
The purpose of this chapter is to discuss the findings of this study. It includes an 
interpretation of the study findings and a discussion of the three research questions posed 
in this study. Additionally, it will discuss limitations which arose during the data analysis 
period as well as implications for social change and recommendations for further action 
and research.  
The aim of this quantitative, retrospective, cohort study was to evaluate 
differences in tumor size, tumor stage, and survival by socioeconomic position in women 
between 20 and 39 diagnosed with breast cancer. Although the incidence of breast cancer 
is lower among women under 40 years of age, young women present with cancer that is 
more advanced and with poorer prognostic characteristics. On both a national and global 
scale, there are apparent socioeconomic, racial, and ethnic health disparities in breast 
cancer incidence and survival (Baquet et al., 2008; Harper et al., 2009). Due to being 
diagnosed at a later stage, the 5-year relative survival rate is slightly lower among women 
diagnosed with breast cancer before age 40 (83%) compared to women diagnosed at ages 
40 or older (90%; ACS, 2010a). 
Summary of Findings 
Hierarchical regression analysis was performed in order to evaluate statistical 
differences in cancer summary stage and tumor size in women aged 20 to 39. An ordinary 
least square regression was utilized to assess differences in survival based on SEP, after 
controlling for race, tumor size, and cancer summary stage. It was found that there were 





However, statistically significant differences in survival based solely on SEP were not 
observed.  
Interpretation of Findings 
This study sought to investigate differences in clinical prognostic characteristics 
of young women, based on SEP. An initial observation was that the SEP Index was 
somewhat evenly distributed, which may be attributed to the overrepresentation of 
ethnic/racial groups within the SEER registry as a whole. That being said, the majority of 
women with a lower SEP Index score appeared to be from the Southern part of the U.S. 
Although the compilation of geographic clusters of breast cancer is beyond the scope of 
this study, it is an area that should be addressed in future research among this population.  
Tumor Size and Socioeconomic Position 
Hierarchical regression analysis was conducted to assess the ability of SEP to 
predict tumor size after controlling for ethnicity and cancer summary stage. Ethnicity and 
cancer summary stage were entered in the partial model in Step 1, explaining 13% of the 
variance in tumor size. After entry of SEP in the full model in Step 2, the total variance 
explained by the model was 13.2%, F(3, 14,692) = 745.71, p < .01. SEP explained .2%, F 
change (1, 14,692) = 42.28, p < .01 (see Table 17). In the final model, all three variables 
made a significant contribution to the model, with cancer summary stage reporting the 
highest beta value (β = .389, p < .01), indicating that as cancer summary stage scores 
increased, tumor size also increased. Ethnicity had the next highest beta value (β = .106, 
p < .01) indicating that non Caucasians have higher tumor sizes than Caucasians. Finally, 





decreased. Based on these results, the null hypothesis that SEP is not a significant 
predictor of tumor size was rejected. 
These results corroborate prior observations (Galobardes et al., 2007; Macleod et 
al., 2000) which states that women with a lower SEP tend to present with a larger tumor 
size. However, not all studies have come to the same conclusion (Robsahm & Tretli, 
2005; Vona-Davis & Rose, 2009). These discrepancies may be attributed to inconsistent 
methods of measuring SEP (Woods, Rachet, & Coleman, 2005), as well as the fact that 
current body of literature pertaining to breast cancer tends to focus on older women, 
whereas the focus of this study was women under 40 years of age.  
Cancer Summary Stage and Socioeconomic Position 
Hierarchical regression analysis sought to determine if SEP predicted survival 
time after controlling for tumor size and ethnicity. Tumor size and ethnicity were entered 
in the partial model at Step 1 and explained 11.8% of the variability in summary stage. 
After entering SEP in the full model in Step 2, the total variance explained for the full 
model remained at 11.8%, F(3, 14,695) = 655.08, p < .01 (Table 20). All three variables 
made a significant contribution to the final model. Specifically, as tumor size increased (β 
= .342, p < .01), so did summary stage. Increases in SEP (β = .017, p = .03) were also 
associated with increases in summary stage. The beta values for ethnicity (β = .016, p = 
.046) revealed that non European-Americans had higher summary stages than European-
Americans. Given the significant contribution of SEP to the final model, the null 





The results of this study indicate that race, tumor size, and SEP make a significant 
contribution to cancer summary stage; specifically, as tumor size and SEP increase, there 
are also increases in cancer summary stage classifications. Additionally, non European-
Americans have a significant higher summary stage classification than European-
Americans. These findings are reflective of prior observations (Bradley, Given, & 
Roberts, 2002) in women across all age groups.  
Survival Analysis 
Hierarchical regression analysis was conducted to assess the ability of SEP to 
predict survival time after controlling for ethnicity, summary stage, and tumor size. 
Ethnicity, summary stage and tumor size were entered into the partial model at Step 1. 
They accounted for 3.3% of the explained variance in survival time. When SEP was 
added to the full model in Step 2, there was no change in the explained variance for the 
full model, F(4, 14,691) = 126.23, p < .01 (Table 22). Results also indicated that 
summary stage (β = -.107, p < .01), tumor size (β = -.082, p < .01), and ethnicity (β = -
.078, p < .01) all made significant contributions to the model, while SEP (β = .010, p = 
.24) did not. Based on the beta values, increases in summary stage and tumor size were 
associated with decreases in survival time. Additionally, European-Americans have a 
higher survival time than non European-Americans.  
Based on the results of this analysis, the null hypothesis that SEP is not a 
significant predictor of survival time after controlling for summary stage, tumor size, and 
ethnicity was accepted. These findings will contribute to the current body of literature on 





well documented, and the findings that have been published differ in their results 
(Klassen & Smith, 2011).  
Theoretical Base 
The theoretical base for this study was driven by the association of the 
independent and dependent variables being investigated. The conceptual model utilized 
highlights the relationship between socioeconomic position, cancer stage, tumor size, and 
survival. To investigate if socioeconomic position has an effect on the biologic makeup 
of breast cancer in young women, variables such as tumor summary stage and size were 
analyzed. Within the context of this study, SEP was utilized to discuss the broader 
groupings of SES.  
As previously discussed, the SEP index utilized for this study is unable to take 
into account health behavior issues which are known to have an impact on breast cancer 
incidence as a whole (Krieger et al., 2009; O'Malley et al., 2003; Wallington et al., 2009). 
Nor does SEER collect data on health habits such as smoking, sedentary lifestyle, breast 
feeding behaviors, or obesity. These confounding factors could not be controlled for and 
are a continued limitation of this study. However, when individual level data are not 
available to determine one’s SEP, it is not uncommon to use an ecological approach in 
creating a census-based index (Woods et al., 2005).  
Implications for Social Change 
The results of this study have the potential to promote positive social change by 
advancing the understanding of breast cancer in young women and of the impact of 





that young women tend to present with cancer that is more advanced and with poorer 
prognostic characteristics. It also has been noted that there are numerous socioeconomic, 
racial, and ethnic health disparities in breast cancer incidence and survival (Baquet et al., 
2008; Harper et al., 2009). This study found that prognostic characteristics such as cancer 
stage and tumor size have an inverse relationship with SEP. As the SEP category 
decreases, tumor size and cancer summary stage increase.  
Recommendations for Action 
In order to raise awareness about breast cancer in young women, it is imperative 
for nurses and doctors to have a discussion with women about their breast cancer family 
history and their own personal breast cancer risk. Public service announcements, events, 
and pamphlets can be created to target specific populations to encourage these women to 
talk with their primary healthcare providers. However, women who have a lower SEP 
may not have the resources or access to consistent quality healthcare. These women are 
of utmost concern in that they tend to present with more advanced clinical symptoms. To 
reach this population, community outreach through women’s health advocacy groups, 
social media outlets, religious, and social service organizations would be beneficial.  
Furthermore, continued discussion of this issue at professional meetings, through 
social media, and with health advocacy organizations will keep the overarching topic of 
breast cancer and SEP relevant and in the forefront of policy makers’ minds.  
Recommendations for Further Studies 
Taking into consideration that women under 40 account for only 6% of newly 





approximately 26% of the United States population, future studies would benefit from 
including geographic areas that are not currently covered by the SEER 17 registry area. 
This proposed design would allow for a larger sampling of women that fit into this 
population. Also, SEER does not include individual level health behaviors or potential 
environmental and occupational exposures. When investigating breast cancer, race, 
ethnicity, and SES are difficult concepts to define in theory and practice. Each concept 
encompasses specific health behaviors, treatment choices, comorbid conditions, as well 
as overall health status (Krieger et al., 2009; O'Malley et al., 2003; Wallington et al., 
2009). Utilizing a data set that includes individual level health behaviors would allow for 
researchers to have a more complete picture of the health behaviors and exposures that 
women have had within their lifetimes that may have contributed to their breast cancer 
statuses.  
Within the current body of literature, there have been discussions regarding the 
impact of race on socioeconomic status (SES) in breast cancer diagnosis. Some studies 
have concluded that when controlling for socioeconomic status, racial disparities do not 
appear to be significant (Maloney et al., 2006); whereas other studies have found that the 
effect of SES on prognostic characteristics is not as strong as that of race (Albano et al., 
2007). 
As previously mentioned, an initial observation of the dataset was that the SEP 
Index was somewhat evenly distributed, which may be attributed to the 
overrepresentation of ethnic/racial groups within the SEER registry as a whole. That 





southern part of the U.S. Although the compilation of geographic clusters of breast 
cancer is beyond the scope of this study, it is an area that should be addressed in future 
research among this population. By geocoding the data, there would be the potential to 
readily identify specific barriers to care at a county level. This would allow policymakers 
to focus outreach efforts and funding to reach those women who need it most. 
Conclusion 
Breast cancer is the second leading cause of cancer death among women in the 
United States and the first cause of cancer related deaths globally. As the understanding 
of what causes breast cancer progresses through science and technology, so should the 
guidelines for screening and treatment. The key to survival among women of all ages is 
early detection and treatment. Raising awareness about the emerging demographics of 
breast cancer in young women could save the lives of many women. No woman should 
have to suffer the consequences of delayed detection and treatment due to the fact that 
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Appendix A:  
Surveillance, Epidemiology, and End Results Program 
Data-Use Agreement for the 1973-2006 SEER Research Data File 
Last Name: TOMÁŠKA 
SEER ID: 12976-Nov2009 
Request Type: DVD 
Delivery 
SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS PROGRAM 
Data-Use Agreement for the 1973-2006 SEER Research Data File 
It is of utmost importance to protect the identities of cancer patients. Every effort has been 
made to exclude identifying information on individual patients from the  
computer files. Certain demographic information—such as sex, race, etc.—has been included 
for research purposes. All research results must be presented or published 
 in a manner that ensures that no individual can be identified. In addition, there must be no 
attempt either to identify individuals from any computer file or to link with a computer file 
containing patient identifiers. 
In order for the Surveillance, Epidemiology, and End Results Program to 
 provide access to its Research Data File to you, it is necessary that you agree to the 
following provisions. 
1. I will not use—or permit others to use—the data in any way other than for  
statistical reporting and analysis for research purposes. I must notify the SEER Program if 
I discover that there has been any other use of the data. 
2. I will not present or publish data in which an individual patient can be identified. I  
will not publish any information on an individual patient, including any information 
generated on an individual case by the case listing session of SEER*Stat. In addition, 
 I will avoid publication of statistics for very small groups. 
3. I will not attempt either to link—or permit others to link—the data with individually 
identified records in another database. 
4. I will not attempt to learn the identity of any patient whose cancer data is contained in the 
supplied file(s). 
5. If I inadvertently discover the identity of any patient, then (a) I will make no use of this 
knowledge, (b) I will notify the SEER Program of the incident, and (c) I will inform no 







6. I will not either release—or permit others to release—the data—in full or in part—to any 
person except with the written approval of the SEER Program. In particular, all members 
of a research team who have access to the data must sign this data-use agreement. 
7. I will use appropriate safeguards to prevent use or disclosure of the information other than 
as provided for by this data-use agreement. If accessing the data from a centralized 
location on a time sharing computer system or LAN with SEER*Stat or another statistical 
package, I will not share my logon name or password with any  
other individuals. I will also not allow any other individuals to use my computer  
account after I have logged on with my logon name and password. 
8. For all software provided by the SEER Program, I will not copy it, distribute it, reverse 
engineer it, profit from its sale or use, or incorporate it in any other software system. 
 
http://seer.cancer.gov/cgi-bin/seer_track/new_request.pl?2 (1 of 2) 
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